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ABSTRACT OF THE DISSERTATION
SYNTHESES OF AZA ANALOGS OF KAINOIDS
by
Mingping Di
Florida International University, 2006
Miami, Florida
Professor Kathleen S. Rein, Major Professor
The kainoids are a class of non-proteinogenic pyrrolidine dicarboxylates that
exhibit both excitatory and excitotoxic activities. These activities are a result of the
ability of the kainoids to act as glutamate receptor agonists by activating ionotropic
glutamate receptors. The parent of this group of compounds is x-kainic acid. Kainic acid
is isolated from the seaweed Diginea simplex and has been used in Asian countries as a
treatment for intestinal worms in children. In addition it is used extensively by
neuropharmacologists for the study of glutamate receptors. Several years ago, the world's
sole supplier of kainic acid discontinued this product. Since that time, other sources have
appeared, however, the price of kainic acid remains significantly higher than it once was.
We have thus been working on synthesizing aza analogs of kainoids which would be less
costly but potentially potent alternatives to kainic acid via the dipolar cycloadditions of
diazoalkanes with trans diethyl glutaconate. These 1, 3-dipolar cycloadditions yielded 2-
pyrazolines or pyrazoles. The 2-pyrazolines may be precursors to aza analogs of kainoids.
The regioselectivity of these 1, 3-dipolar cycloadditions and isomerization of the 1-
pyrazolines to 2-pyrazolines was evaluated. Reductions of the 2-pyrazolines yielded aza
analogs of kainoids.
vi
TMS diazomethane, due to the commercial availability, has been frequently used
as a synthetic reagent in 1, 3-dipolar cycloadditions, particularly in the preparation of
novel amino acid analogs. A survey of the recent literature indicates that the
regioselectivity of the double bond isomerization of TMS substituted 1-pyrazolines is
variable and at first glance, unpredictable. In an effort to develop a mechanistic rational
for the isomerization which could account for the products obtained, a systematic survey
of dipolar cycloadditions between TMS diazomethane and O, P-unsaturated
dipolarophiles was undertaken. It was suggested that the steric demand of the
dipolarophiles had a profound effect on both the relative stereochemistry of dipolar
cycloaddition reactions of TMSCHN 2 and the preferred direction of isomerization of the
resulting 1 -pyrazoline.
vii
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1. Introduction
L I Jonotropic Glutamate Receptors (iGluRs)
The acidic amino acid (5)-glutamic acid (Glu) 1 (Figure 1) is a major excitatory
neurotransmitter in the mammalian central nervous system (CNS), where it plays an
important physiological role in mediating synaptic plasticity and processes such as
learning and memory. Glu exerts strong excitatory action on most neurons in the CNS. It
was shown to have powerful excitatory effects on neurons more than forty years ago.
Besides having a key role in excitatory transmission, Glu has also been shown to be
implicated in neurodegenerative processes. 2 This was originally based on the
observations developed by Lucas and Newhouse 3 that administrating glutamate
systemically to mice induced degeneration of retinal neurons and has been well
documented over the last forty years through numerous in vitro and in vivo experiments. 4
Strong support has been provided for the involvement of at least partly a cytotoxic action
of Glu in acute neurologic diseases such as ischemia, stroke, trauma and hypoglycemia.
Glu may also contribute to certain chronic neurodegenerative diseases such as
Huntington's chorea and Alzheimer's disease,5 although the actual mechanisms remain to
be characterized. 2
Glu acts by binding to glutamate receptors, which can be divided into two types:
metabotropic glutamate receptors (mGluRs) and ionotropic glutamate receptors (iGluRs).
The mGluRs belong to the superfamily of G-protein coupled receptors and comprise
mGluR1-8.6' 7 The iGluRs are cation-selective ligand-gated ion channels, regulating the
flux of cations (Na+, K+, and Cat) across the synaptic membrane. They have been
classified into three classes: NMDA, AMPA and KA receptors based on their selective
1
interaction with the agonists N-methyl-D-aspartic acid 2 (Figure 1), 2-amino-3-(3-
hydroxy-5-methyl-4-isoxazolyl)propionic acid 3 (Figure 1) and kainic acid 4 (Figure 1),
respectively.',8 NMDA receptors are distinct from AMPA and KA receptors due to the
presence of potent and selective NMDA receptor antagonists. The difference between
AMPA receptors and KA receptors is less distinct than those distinguishing NMDA
receptors from AMPA and KA receptors, thus the latter two subtypes were often
collectively referred to as non-NMDA receptors.9 While NMDA shows highly selective
affinity for NMDA receptors, KA also has a moderate affinity for AMPA receptors in
addition to its high affinity for KA receptors.0 -12 Therefore, the descriptive names for
Glu receptor subtypes (AMPA and KA receptors) may be rather misleading due to a
nonexisting specificity, and alternative names have been proposed.13 However, none of
them have been widely accepted, and the aforementioned names are still predominantly
used.9
Based on our knowledge of the iGluRs,14-1' the NMDA receptors gate an ion
channel that is highly permeable to Ca2+ but also allows passage of Na+ and K+. They
show a voltage dependent block by Mg2 and Zn2 and are modulated by glycine, a
coagonist of these receptors. NMDA receptors are widely distributed in the mammalian
CNS and enriched in the cerebral cortex and hippocampus. They have been shown to be
implicated in long-term potentiation (LTP), a form of synaptic plasticity in which NMDA
receptors activation triggers a long-lasting increase in synaptic efficacy. This long-term
potentiation can last for weeks and plays an important role in some forms of memory and
learning processes mediated by the hippocampus which is believed to control the
consolidation of short-term memory into long-term memory. Both the AMPA receptors
2
and kainate receptors gate an ion channel that is selective for monovalent cations Na+ and
K, and also for some receptors Ca2. They mediate fast excitatory synaptic transmission
in the CNS and are rapidly activated and desensitized by glutamate. Kainate receptors
have been demonstrated to be involved in the induction of LTP at synapses where
NMDA receptors do not have a role, in particular at mossy fiber synapses in the
hippocampus.19
0 0 4 3,-COOHOH OH
HO - HO OH HO / H 5 COOH
HO -NHfX OO
(S)-Glutamic acid NMDA (S-AMPA (-)-x-Kainic acid
1 2 3 4
NMDA receptor subuits AMPA receptor subunits KA receptor subunits
NR1 NR2A-D NR3A,B GluR 1-4 GluR5-7 KA1,2
Figure 1. Multiplicity of iGluRs and structure of selected agonists.
The cloning of a number of iGluR subunits supported the aforementioned
classification of iGluRs which is originally derived primarily from agonist pharmacology,
but in the meantime brought about a subdivision of the three classes of iGluRs.2 The
iGluR receptor subunits can be divided into six groups (Figure 1). One group, containing
the iGluR1-iGluR4 subunits, forms the AMPA receptors. The low affinity KA receptor
subunits, iGluR5-iGluR7, and the high affinity KA receptor subunits, KA1 and KA2,
comprise the KA receptors, whereas the NMDA receptor subunits are divided into three
groups-the NR1, NR2A-NR2D, and NR3A, B.2 Each of these receptor subunits is
membrane-anchored and is believed to contain a large extracellular N-terminal domain,
3
three membrane-spanning domains, and an ion channel-forming reentrant loop.] It is
believed that these subunits combine with other subunits from the same class to form
pentameric or more likely tetrameric receptor ion channel complexes through a
homomeric and/or heteromeric assembly.2 2 2 4
Glutamate receptors are thought to convey most of the fast excitatory
transmission in the mammalian CNS and to be crucial for induction and maintenance of
various forms of synaptic plasticity such as long-term potentiation (LTP) and long-term
depression (LTD). 25, 2 6 In addition, glutamate receptors are thought to be crucially
involved in neuronal degeneration associated with acute brain insults such as cerebral
ischemia /hypoxia, hypoglycemia, cerebral trauma and epilepsy 27, 28 and certain slowly
progressing neurodegenerative diseases such as Huntington's chorea, Parkinson's disease,
Alzheimer's disease.5,27,29 It is now generally agreed that all subtypes of the GluRs are
potential targets for therapeutic intervention in a number of diseases. Neuronal damage, a
phenomenon referred to as excitotoxicity2 9 , 30 can be caused by excessive activation of
glutamate receptors. Depending on the type of brain pathology, a pathophysiological
overstimulation of glutamate receptors can be induced by an enhanced release of
excitatory amino acid neurotransmitters such as Glu, increased levels of excitotoxins in
the cerebral parenchyma, an impaired neurotransmitter uptake or metabolism, an
imbalance between excitatory and inhibitory stimuli or an enhanced efficacy of the
glutamatergic neurotransmission.27,31 Prolonged glutamate receptor activation can result
in a serious disturbance in the cellular signaling system which is mainly caused by
uncontrolled transmembrane ion fluxes through glutamate receptor-mediated ionophores.
In particular, it has been shown that the entry of Ca2 + is crucially implicated in glutamate-
4
induced neuronal injury and death. "2 3 3 Among the iGluRs, NMDA receptors have
received extensive attention as they can directly mediate abnormal rises in intracellular
Ca> that may induce degenerative process. However, an involvement of non-NMDA
receptors in pathological processes has also been demonstrated. 34 -37 For example,
historically, kainate receptors have long been associated with epilepsy.
Kainate receptor subunit proteins are widely expressed in excitatory and
inhibitory neurons throughout the brain.3840 Kainate receptors are targeted to a variety of
presynaptic and postsynaptic locations often within the same neuron. At these locations,
they perform specific tasks associated with the regulation of presynaptic function of
glutamate transmission and transmission mediated by other transmitters, most notably y-
aminobutyrate (GABA), postsynaptic neurotransmission, or regulation of membrane
excitability.41 44 Kainate receptors have been clearly established as major players in
excitatory transmission. It has been demonstrated that kainate receptors at mossy fiber-
CA3 synapses play an important role in frequency-dependent synaptic facilitation, a form
of short-term plasticity in which the strength of transmission increases with repetitive
stimulation. 45' 46 Kainate receptors have also been shown to be required for long- term
potentiation (LTP) between mossy fibers and CA3 pyramidal cell.' 9 '4 The
pharmacological characterization of kainate receptors has been hampered by a lack of
selective ligands. Typically, natural products such as kainic acid (Figure 1, 4) and domoic
acid (Figure 2, 13) were used as reference standard agonists, although they also show
interaction with AMPA receptors. KA (Figure 1, 4) and domoic acid (Figure 2, 13) are
two naturally occurring pyrrolidine dicarboxylates in which the amino groups are
incorporated into pyrrolidine rings, making them the confo ationally restricted
5
glutamate analogs. They are not only potent kainate receptor agonists but are also known
to have highly neurotoxic effects and have therefore been extensively used as
pharmacological tools. 47
1.2 Kainoids
(-)-a-Kainic acid (Figure 1, 4) is the parent of a well-known group of naturally
occurring and synthetic nonproteinogenic pyrrolidine dicarboxylic acids known as the
kainoids which have general structure 5 (Figure 2). They all have three asymmetric
centers at carbons 2, 3, 4 of the pyrrolidine ring. They vary in the nature of the C-4
substituent generally containing r-unsaturation, and the absolute configuration at this
position. This variation gives rise to various members of the kainoid family. The parent
member, (-)-a-Kainic acid (Figure 1, 4, originally known as digenic acid) was first
isolated in 1953 from the Japanese marine algae Digenea simplex48 along with its C-4
epimer (+)-allokainic acid (Figure 2, 6). Since then it has been found to occur in the
related algae Centrocerus clavulatum49 and in the Corsican moss, Alsidium
helminthocorton.0 ',5
1
(-)-Domoic acid (Figure 2, 13) was originally isolated in 1958 from another
Japanese marine algae - the warm water algae Chondria armata.2 Since then it has been
found in the phytoplankton Nitzschia pungens5354 and the algae Alsidium corallinum5 0 . A
number of kainoids related to domoic acid have also been isolated from the same algae,
which include the isodomoic acids A-F (Figure 2, 14-19),5 56 the C-5' domoic acid
diastereomer (Figure 2, 20)57 and the domoilactones A and B (Figure 2, 21a and 21b).5
The acromelic acids A and B (Figure 2, 8 and 9), containing a functionalized 2-pyridone
6
as the C-4 substituent, were found in a quite different organism to the previously
described kainoids, namely the poisonous Japanese mushroom Clitocybe acromelalga.59
60 They were first isolated in sub-milligram quantities in 1983. Since their isolation, a
R 3 COOH o-COOH ,-COOH
52
COOH N COOH N COOH
H H H
5 (+)-a-allokainic acid CPAA
6 7
HOOC O O HOOC
NH NH NH 
-N
O COOH
-COOH 
- COOH ,, -COOH .- COOH
N COOH N COOH N COOH N COOH
H H H H
Acromelic acid A Acromelic acid B Acromelic acid C Acromelic acid D
8 9 10 11
N OH COOH COOH - COOH
\ OOH
r .- cooH
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Figure 2. Representative synthetic and naturally occurring kainoids
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number of other kainoids have been isolated including the acromelic acids C, D and E
(Figure 2, 10-12) which have been shown to be minor constituents of Clitocybe
acromelalga. 1,62
Interest in the kainoids arose from their pronounced insecticidal, anthelmintic and
principally neuroexcitatory properties. The ability of the kainoids to be insecticides has
long been used in Japan. An extract of red algae, from which kainic acid and domoic
acid have been isolated, was used for its fly-killing properties. The algae Digenea simplex
has been used for its anthelmintic properties for more than a thousand years in Japan.63
The active component, (-)-a-Kainic acid (Figure 1, 4) has been shown to have a strong
anthelmintic effect, about 10 times that of santonin without side effects.6 3 Similar
properties have been reported for (-)-domoic acid (Figure 2, 13).
The pronounced neuroexcitatory properties of the kainoids have been well
documented and this class of molecule is now inextricably associated with neuroscience
research. 1'64-66 The kainoids have been shown to selectively block neuronal processes
and thus are valuable tools in the study of neurofunctioning. The neuronal degeneration
caused by the kainoids have been shown to closely resemble that observed in patients
suffering from neuronal diseases such as epilepsy 67 and Huntington's chorea 68. In
addition, it is possible that neuronal death caused by kainoids is a good experimental
model for neuronal cell loss in senile dementia. 64 The potent neuroexcitatory activity of
the kainoids can be attributed to their action as conformationally "locked" analogues of
the neurotransmitter L-glutamic acid (Figure 3), causing neuronal death in glutaminergic
system found in the brain. Numerous structure-activity investigations of the kainoids and
their analogues have been carried out.9' 69-74 Based on these results, it has been shown that
8
the nature of C-4 substituent, its conformation and stereochemistry play a critical role in
binding and functional activation at the recognition site. The activity of the kainoids is
effectively lost if the absolute configuration of any one the three stereocenters is
inverted.14 Further, a single study suggests that the activity of the unsubstituted kainoid,
2-carboxy-3-pyrrolidine-3-acetic acid (CPAA) (Figure 2, 7) is significantly less than that
of kainic acid.75 (-)-Domoic acid (Figure 2, 13) has been shown to be more
neuroexcitatory than (-)-a-kainic acid (Figure 1, 4). It has been identified as the toxin in
paralytic shellfish poisons (PSPs) and was determined to be responsible for an outbreak
R -CO 2 H CO 2 H
N CO2 H H2 N CO 2 H
H
Kainoids (S)- Glutamic acid
1
Figure 3. Structural similarity of kainoids and (S)-glutamic acid
of mussel poisoning in Canada in 1987.7,77 During the incident, over a hundred people
were hospitalized as a result of the consumption of mussels contaminated with domoic
acid (Figure 2, 13). Among them, three people died and many of the survivors of this
incident continue to suffer severe dementia and memory loss. The contamination of the
mussel was thought to occur by ingestion of domoic acid by the mussels through its main
food source, a diatom, Nitzschia pungens, a primary producer of the toxin, which had
formed a dense bloom near the mussel bed. In the U. S., a domoic acid incident occurred
in Monterey Bay in 1991, and spread as far north as Oregon and Washington.
7 8
'
79
9
Fortunately, due to extensive monitoring of shellfish, no human exposures were reported.
However, with increased international commerce, contaminated seafood products have
the potential for rapid widescale distribution.
Of the naturally occurring kainoids, the acromelic acids have been shown to have
the most potent neuroexcitatory activity. The acromelic acid B (Figure 2, 9) was shown to
be slightly less potent than acromelic acid A (Figure 2, 8) 80,81 and both were shown to be
more potent than domoic acid. Acromelic acid A and B (Figure 2, 8 and 9) were reported
to be lethally toxic to mice at a dose of 7 and 8mg/kg repectively. Acromelic acid C
(Figure 2, 10) was shown to have similar lethal dose of 10mg/kg.61 Acromelic acid D
(Figure 2, 11) was shown to be a neuroexcitant as potent as kainic acid (Figure 1, 4).82
Synthetic acromelic analogues such as 22-24 (Figure 4) have also been tested for
neuroexcitatory activity and the phenyl derivative 22 (Figure 4) showed activity
comparable to kainic acid (Figure 1, 4).3-86 The phenol derivative 23 (Figure 4) was
shown to be more potent than acromelic acid B (Figure 2, 9) or domoic acid (Figure 2,
13). The methoxyphenyl derivative 24 (Figure 4) was 3- to 5- fold more potent than
acromelic acid A ( Figure 2, 8).
1.3 Crystal stuctures of iGluRs ligand binding cores: Molecular mechanisms underlying
ligand-binding affinity and specificity and iGluR gating properties
iGluRs are modular proteins which are formed by distinct ligand-binding and
channel-forming domains.87,88 They have a similar overall structure in which four
homologous subunits surround a central cation-selective pore. A clam shell-like ligand-
binding core contains the agonist and antagonist binding sites 89,90 and is connected to the
10
three transmembrane domains (M1, M3, M4) and a reentrant loop (M2) that form the ion
channel (Figure 5). Eukaryotic iGluRs contain an amino-terminal domain (ATD) that
does not participate in ligand binding,91 but plays an important role in subtype-specific
assembly 92 and mediation of intersubunit interactions.93 The ~2O-aa between the end of
the ATD and M1 (termed Si) form one half of the ligand binding core, and the 140-aa
S -CO 2HR
N CO 2H
H
22R=H
23R= OH
24 R = OMe
Figure 4. Synthetic acromelic acid analogues
between M3 and M4 (S2) is the second half 8 9' The structural elements required by the
wild-type iGluR receptors to respond to agonists and antagonists are contained in the
S1 S2 domains.91 In the cases of AMPA, kainate, and NMDA receptors, S1S2 domain can
be expressed as a water-soluble constuct that is independent of the transmembrane
domains and retains wild-type ligand binding affinities.8 9' 94' 95 The S1S2 constructs that
have been expressed include the ligand-binding core of the AMPA receptor GluR2
(GluR2-S1 S2J)96, of the NMDA receptor NR1 97 and of the kainate receptor GluR5 and
GluR6.98 1400 The successful X-ray crystallographic resolution of structures of these
constructs in complex with different agonists and antagonists have provided a wealth of
information about binding modes and mechanism of action of iGluRs.24, 96, 98, 101, 102
11
A. B.
S1 S2
SP NTD M1M2M3 M4
Amino
Terminal
Domain cut
S2 Loo p1
Domain 2 Kaint Domain 1
7 lcut F C-Term
- To TM4
1 4 To TM123
rom TM123
C
Figure 5. A. iGluR topology, showing the Si and S2 segments in turquoise and pink, respectively. 'cut' and
'linker' represent the edges of the S1S2 construct. The ligand binding domain comprising Sl and S2 can be
expressed as a soluble polypeptide, excluding the amino terminal domain and transmembrane domains
M1-M4. SP, signal peptide. B. Ribbon representation of the structure of GluR2-S1S2 in complex with kainate
( black ball-and-stick representation) (pdb code 1GR2). Arg 485 from helix D, Ser 654 and Thr 655 from
helix F, and Thr 686 and Glu 705 from helices H and I either interact with kainate or are involved in
interdomain contacts. TM, transmembrane domain. These models are modified from Nanao et al. 100 and
Armstrong et al.90.
1.3.1 AMPA receptor
High resolution structures of GuR2 Si S2 in the apo state and in the presence of
glutamate (Figure 1, 1) AMPA (Figure 1, 3), kainate (Figure 1, 4) and the antagonist 6,7-
dinitro-2,3-quinoxalinedione (DNQX) (Figure 6, 25) have been determined. 96
Comparison of these five structures has revealed reasonable mechanisms underlying
receptor activation, antagonism and the molecular basis for ligand specificity.
90
'
96
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In the apo state or antagonist-bound state, the ion channel is closed. This closed
channel state has a ligand binding core containing separated domains 1 and 2 and an open
receptor cleft. The open-cleft conformation in the apo state is stabilized via intradomain
interactions. The antagonist DNQX bound state possesses the open-cleft conformation
stabilized via antagonist-receptor interactions.
H
O N 2CI H
O NO 2  HOOC COOH CI
H H2N CH 3  HNNO 2S
O \O
6,7-dinitro-2,3-quinoxalinedione 2S, 4R-4-methylglutamate cyclothiazide
(DNQX)
25 26 27
Figure 6. Agonist (26), antagonist (25) and allosteric modulator (27)
Interestingly, the receptor binding sites for the a-substituents of glutamate (Figure
1, 1), AMPA (Figure 1, 3), and kainate (Figure 1, 4) are essentially the same. a-Carboxyl
and a-amino group directly make contact with the ligand binding core through seven ion
pair and hydrogen bonding interactions to domains 1 and 2. a-Carboxyl group forms
essential interaction with the guanidinium group of Arg-485(domain1), the main-chain
NH group of Thr 480 (domain 1) and Ser 654 (domain2). Arg 485 is conserved in all
glutamate receptors. The a-amino group is bound to domain 1 and 2 by interactions with
a carboxylate oxygen of Glu 705, the carbonyl oxygen of Pro 478 and the sidechain
hydroxyl of Thr 480.
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In contrast, the binding sites for the anionic position attached to y carbons of these
three agonists are distinct. The 'y' substituent of AMPA (Figure 1, 3), isoxazole ring,
binds to different sites from the y-carbonyl of kainate and glutamate. It interacts with a
water molecule (#4) which forms interactions with an a-carbonyl oxygen, and residues at
the base of helix F. The inclusion of this water molecule by AMPA converts AMPA into
a good bioisosteric mimic of glutamate. The isoxazole nitrogen forms a hydrogen bond
with the backbone NH of Glu-705.
The glutamate and kainate binding clefts mainly differ in the position of Leu-650,
which moves substantially further into the cleft in the glutamate-bound state and thus
would sterically clash with the kainate isopropenyl group when kainate structure is
superimposed with the glutamate-bound structure. When this leucine is replaced by a
valine or a threonine in GluR1, the affinity of the resulting mutants for kainate is
significantly increased, with the EC50 decreased by 6- and 20-fold respectively.'03 This
can be attributed to the adoption of a glutamate-like conformation by the ligand binding
core in complex with kainate (Figure 1, 4) after Leu 650 is replaced by valine or
threonine.
The extent of the domain closure the ligand can induce appears to have a close
correlation with ligand efficacy. The full agonists of AMPA receptors, such as glutamate
(Figure 1, 1) and AMPA (Figure 1, 3) induce the same greatest degree of domain closure
(~ 20') relative to the unligated (apo) form. In contrast, kainate (Figure 1, 4), a partial
agonist at AMPA receptors,104' 105 induces only ~ 12 of domain closure, whereas in the
antagonist DNQX bound state, a small degree of domain closure (~ 2.50) is induced. It
has thus been proposed that substantial closure of the ligand binding cleft results in
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activation (opening) of the ion channel gate. The intermediate domain closure induced by
the partial agonist results in an intermediate conformational change of the receptor at the
transmembrane gate, and thus partially activates the ion channel. Antagonists, stabilizing
the ligand binding core in an open-cleft conformation, induce no or very small
conformational change of the receptor, precluding the opening of the ion channel gate.
1.3.2 Kainate receptor
Among the ionotropic glutamate receptors, the kainate receptor is the last one for
which the crystal structures of the receptor ligand binding cores have become available.
Prior to this, the GluR2-S 1 S2 structure had been used as a model in the study of kainate
receptors, since the primary sequences of the agonist-binding domains of AMPA and
kainate receptor subunit are similar (48-55%).106', 107 However, only limited inferences
can be obtained for the kainate receptor from a comparison with the GluR2 structure
since the properties of AMPA and kainate receptors are different. This situation changed
when crystal structures of the GluR5 and GluR6 ligand binding cores were acquired in
complex with glutamate (Figure 1, 1), kainate (Figure 1, 4), domoic acid (Figure 2, 13)
and (2S, 4R)-4-methylglutamate (Figure 6, 26),~1 a ligand that has a 1000-fold higher
affinity for kainate versus AMPA receptors. 10' 10 This has enabled the uncovering of the
modes of agonist binding of the kainate receptor, the identification of the differences in
the mode of agonist binding and the intersubunit contacts between the GluR2, GluR5 and
GluR6 subunits, and thus the exploration of the relevance of these structural differences
to the function of AMPA and kainate receptors. The molecular mechanisms underlying
receptor selectivity have to some extent been revealed.
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The Si S2 domains of GluR5, GluR6, GluR2 and NR1 have essentially the same
overall folding pattern, with all of them sharing a bilobate structure. However, the ligand
binding pocket in GluR6 (volume 255 15 A3) is smaller that that in GluR5 (volume 305
6A3 ), but larger than that for GluR2 (volume 218 4A 3), due to amino acid side chain
substitutions unique to the binding site of each subunit. The c-carboxyl and a-amino
groups of glutamate bind to the ligand binding cores of GluR5 and GluR6 through ion
pair and hydrogen bond contacts with conserved Arg and Glu side chains, and with main
chain peptide bonds in both domains 1 and 2, in a way nearly identical to that observed
for AMPA receptor GluR2 subunit.96 The glutamate y-carboxyl group binds only to
domain 2 and interacts through hydrogen bonding with residues near the N termini of
helices F, H, and I that are same in GluR5 and GluR6, whereas, in the GluR2 glutamate
complex, all of these are solvent mediated except a pair of hydrogen bonds formed with
the hydroxyl group and main chain NH group of T655 at N terminus of helix F.
Some water molecules are trapped in the kainate GluR5 and GluR6 ligand binding
pocket, similar to that observed in the GluR2 glutamate complex.96 Consistent with the
larger volume of the ligand binding pocket in the kainate receptor structures, five and six
water molecules are contained in the GluR6 and GluR5 glutamate complex, compared to
four trapped water molecules in the GluR2 complex. One of the additional water
molecules in the kainate receptors interacts via hydrogen bonding with the ligand a-
amino group and together with another water molecule forming a network linking domain
2 with domain 1. It would be expected that this interdomain contact can contribute to the
stability of the glutamate-bound kainate receptor (GluR5 and GluR6) complex, which is
better than that of AMPA GluR2 glutamate complex as indicated by the domain closure
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of ca. 26" of the kainate (GluR5 and GluR6) glutamate bound complex relative to the apo
structure of GluR2-S 1 S2, being ca 6 larger than that of the GluR2-S 1 S2 glutamate
complex.
Kainic acid (Figure 1, 4) has a much higher affinity for Kainate receptors (Kd 56
nM for GluR6 S1 S2) than that for AMPA receptors (Kd 14.5 pM for GluR2 S1 S2).96 98
The underlying mechanisms for this observation has been put forth.98 One feature that
contributes to high-affinity binding of Kainate to GluR6 is that, in GluR6 kainate
complex, the hydrophobic 4-isopropenyl group is completely shielded from water, which
is energetically favorable compared to its environment in aqueous solution. The second
mechanism involves the high degree of domain closure in GluR6 kainate complex (23.3*),
which is only slightly less than that for GluR6 glutamate complex (260) and much greater
than that observed for the GluR2 kainate complex (12.30). This permits the formation of
multiple interdomain contacts between domain 1 and helix F in domain 2 in GluR6
kainate complex, which are not observed in the GluR2 kainate complex due to its smaller
degree of domain closure. The higher degree of domain closure in the GluR6 kainate
complex possibly results from the reduced steric hindrance between the ligand
isopropenyl group and the amino acid residues within the ligand binding core. The
isopropenyl group is placed between L650 and M708 in GluR2 kainate complex whereas
it exists between the smaller side chains V654 and T710 in the GluR6 kainate complex,
resulting in a higher degree of domain closure.
Compared to glutamate (Figure 1, 1), (2S, 4R)-4-methylglutamate (Figure 6, 26)
derived from the introduction of a single methyl group on the C7 atom of glutamate
(Figure 1, 1) has a 170- and 100-fold higher affinity for GluR5 and GluR6 respectively,
17
but 14- and 28-fold lower affinity for the AMPA receptor GluRl and GluR3.1 9 Probable
mechanisms for the high affinity of (2S, 4R)-4-methylglutamate (Figure 6, 26) for kainate
receptors have been suggested. First, (2S, 4R)-4-methylglutamate (Figure 6, 26) binds to
GluR6 in a way identical to that for glutamate (Figure 1, 1) except that the 4-methyl
group makes additional contacts with Y457 and V654 via Van der Waals contacts,
providing extra binding energy. Second, the hydrophobic methyl group is shielded in the
ligand binding cavity, which is energetically favorable compared to its environment in
aqueous solution. Third, there are more extensive contacts between domains 1 and 2 in
kainate receptor (2S, 4R)-4-methylglutamate complex than AMPA receptor (2S, 4R)-4-
methylglutamate complex, which contribute to the stability of agonist complexes.
Superimposition of the GluR2 glutamate and GluR6 (2S, 4R)-4-methylglutamate
structures reveals that both structures are almost superimposable except that 4-methyl
group has an unfavorable contact with the GluR2 L650 chain, which is substituted by the
smaller valine side chain in GluR6.
1.3.3 Gating mechanism
Ligand-gated ion channels convert chemical signals into electrical impulses
through opening of a transmembrane pore after binding one or more neurotransmitter
molecules. The typical action of an agonist at a receptor includes activating the receptor
followed by either deactivation of the receptor (agonist unbinding) or desensitization of
receptor to protect the cell from overactivation. Receptor desensitization, an inactive state
with agonist remaining tightly bound, is a functionally important phenomenon occurring
in most ligand-gated ion channels such as iGluRs.' 110
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It has been indicated that iGluR ligand binding cores are assembled as dimeric
units in a tetrameric form which has local rotational 2 fold axes of symmetry and the
channel-forming region of iGluRs forms a tetramer with an approximate 4-fold axis of
rotational symmetry.24,$$ 96, 99, 100, 111 It has been shown that stabilization of the dimer
interface by either mutations or allosteric modulators such as cyclothiazide (Figure 6, 27)
results in the decrease of desensitization and destabilization of the dimer interface
increase the desensitization.] 00
A mechanism for the activation and desensitization of the iGluRs has been
proposed (Figure 7).4, 96, 100 112 When agonists bind to the receptor, it probably first
interacts with domain 1, which promotes the rotation of domain 2 toward domain 1 to
close the ligand binding domain and trap the agonist in the ligand-binding cleft. Upon
activation, the dimer interface is still intact and the conformational stress resulted from
domain closure is translated to the ion channel gate, and thus the gate is opened. It has
been suggested that the interaction between adjacent domain 1 keeps the domains fixed
relative to each other in the moving of the channel during gating caused by rotation of
domain 2 toward domain 1. When the agonist is present for a longer time, the dimer
interface rapidly destabilizes and a rearrangement of the dimer interface takes place. The
consequence of this action is that no conformational changes caused by the domain
closure are translated to the ion channel gate and the decoupling of domain closure from
the channel gate occurs, which promotes entry to the desensitized state to protect the cell
from overactivation. For the native receptor, the activation of the receptor is faster than
the desensitization of the receptor because the energy barrier for receptor desensitization
is higher than for receptor activation. However, the receptor is more stable in the
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Open cleft Open cleft Closed cleft
Constrained dimer Constrained dimer Constrained dimer
Closed channel Closed channel Open channel
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.D1 D1
D1 D1
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Closed cleft
Relaxed dimer
Closed channel
Figure 7. Glutamate receptor activation and desensitization model. This model is modified from Sun et al.24
D1 and D2 represent domain 1 and domain 2 of the ligand-binding core, respectively. Each subunit binds a
single agonist (red circle) and has three different conformations: closed, open and desensitized.
Transmembrane regions of each subunit are represented by a single green cylinder and the N-terminal domain
(ATD) is not shown in the model.
desensitized state than in the activated state, and thus most of the receptors enter the
desensitized state after the receptor is incubated with the agonist for a prolonged duration.
The binding of agonist to iGluRs induces a complex allosteric transition which
involves rearrangements of both the ligand binding core and the ion channel. It should be
noted that the information about iGluR binding and gating mechanisms that has been
obtained so far, some of which are described above, has stemmed from the analysis of the
crystal structures of the iGluR Si S2 constructs other than the crystal structures of the
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intact iGluRs which have not been successfully obtained. Clearly, crystal structures for
the intact iGluRs in different states such as apo, agonist-bound (active or desensitized), or
antagonist-bound states are needed to completely understand the iGluR binding and
gating mechanisms.
1.4 Synthesis of kainoids
A considerable synthetic challenge is involved in the synthesis of kainoids. The
formation of a pyrrolidine with two carboxylic acid groups with specific stereochemistry
at the three contiguous chiral centers around the ring needs to be addressed. Special
consideration needs to be given to the cis disposition of the C3 and C4 substituents
contained in most of the naturally occurring kainoids. Meanwhile, an ideal synthesis
should enable the introduction of various side chains at the C4 position in a convergent
way to afford all the known kainoids and various kainoid analogues in the relatively high
yield.
The many synthetic approaches to the kainoids can be conveniently divided into
two categories: those that involve pyrrolidine ring synthesis from an acyclic precursor
and those that involve the modification of an existing pyrrolidine ring. The published
syntheses of kainoids are too many for a comprehensive review. A few representative
examples of various approaches are presented.
1.4.1 Pyrrolidine ring synthesis from an acyclic precursor
The majority of the approaches to the construction of the kainoid ring system
involve the stereoselective formation of the 3, 4-bond. Typically, the configuration at C2
of the kainate ring is derived from a readily available chiral starting material (often an
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Figure 8. Intramolecular ene reaction as a key step in the synthesis of kainoids
amino acid) and it is this stereocenter that directs the formation of two new stereocenters
at C3 and C4. Selected examples are described below.
A stereocontrolled intramolecular ene reaction has been used as the key step in
the enantioselective synthesis of kainic acid.' 13-116 As shown in Figure 8, the ene
cyclization reaction occurred to provide the desired trisubstituted pyrrolidine 29 under the
steric control of the C2 stereocenter when the key intermediate diene 28 synthesized from
L-glutamic acid was subjected to thermolysis in hot toluene.11 3 The pyrrolidine 29 was
converted to a-kainic acid (Figure 1, 4) in six straightforward steps.
An intramolecular hetero-Diels-Alder cyclization has been employed to
synthesize a-kainic acid (Figure 9).11 The key intermediate 30, originally prepared from
diethyl L-tartrate and not isolated, spontaneously underwent the [4+2] cyclization to
furnish the tricyclic adduct 31 with the desired stereoselectivity, which was converted to
a-kainic acid (Figure 1, 4) after several steps including ketal hydrolysis, hydrogenation,
amine protection and manipulation of the 3,4-substituents.
A cobalt-mediated cyclization reaction has also been used as the key step in
kainoid synthesis (Figure 10).118,119 By treatment with cobaloxime (I), cyclization of the
iodide 32 provided a mixture of the seperable syn- and anti- pyrrolidines 33 and 34 in the
ratio of 5:3 with 80% yield. Significantly, the isopropenyl group was successfully
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Figure 9. Intramolecular hetero-Diels-Alder cyclisation as a key step
in the synthesis of kainoids
established at the C4 position along with the formation of the pyrrolidine ring. Compound
33 was converted to a-kainic acid (Figure 1, 4) in six additional steps while the anti-
isomer 34 was elaborated to allo-kainic acid (Figure 2, 6) in a similar way. The same
methodology has also been utilized in the preparation of the domoic acid analogue and
acromelic acid A (Figure 2, 8).120, 121
BnO BnO BnO
Cobaloxime (1) TBDMSO B\DM
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CO2 Ph CO2Ph C0 2Ph32
32 33 34
Figure 10. Cobalt-mediated cyclisation reaction as a key step in the synthesis of kainoids
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Figure 11. Pauson-Khand reaction as a key step in the synthesis of kainoids
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The Pauson-Khand reaction has been employed in the kainoid synthesis.12-4 By
treatment with dicobalt octacarbonyl followed by trimethylamine N-oxide, the ene-yne
35 derived from glutamic acid underwent the Pauson-Khand reaction to furnish a 1.7:1
mixture of inseperable enone diastereomers 36 and 37 in a yield of 95% (Figure 11).122
The enone 36 was elaborated to a-kainic acid (Figure 1, 4) after several steps.
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Figure 12. Tandem Michael addition as a key step in the synthesis of kainoids
A tandem Michael addition has been employed in the kainoid synthesis. 125 ,126 As
shown in Figure 12, the amine 38 derived from D-serine was reacted with the alkene, 2-
nitro-3-methyl-buta-1,3-diene, generated in situ from the nitro compound 39 to provide
the desired pyrrolidine 40 in 88% yield. The nitro group of 40 was then removed regio-
and stereoselectively by a hydride transfer reaction in order to synthesize a-kainic acid
(Figure 1, 4). The same synthetic methodology has also been employed in the synthesis
of acromelic acid A (Figure 2, 8).127
Takano and coworkers have employed a 1,3-dipolar cycloaddition reaction of an
azomethine ylide to construct the pyrrolidine ring (Figure 13).12 On heating to 310 C in
xylene, aziridine 41 was converted to the all syn-adduct 42 with a yield of 70%. In this
case, 2, 3 and 4, 5 bonds of the pyrrolidine ring were established in the same reaction.
The adduct 42 was transformed to a-kainic acid in a number steps which include
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Figure 13. 1,3-Dipolar cycloaddition reaction as a key step in the synthesis of kainoids
inversion of C2 stereochemistry. The same group has used a similar methodology to
synthesize acromelic acid A and B (Figure 2, 8 and 9).129, 130
Yoo et al. have utilized an intramolecular Michael reaction to construct the
pyrrolidine ring in the synthesis of kainoid analog CPAA (Figure 2, 7) including seven
steps in total.13 1 Thus the key intermediate 43, prepared from 3-amino-1-propanol, was
treated with NaOEt to give a mixture of 44 (trans:cis=95:5) in 94% yield. The trans
isomer of 44 was converted to 7 after acid hydrolysis.
CO 2Et CO 2Et < CO 2H
NaOEt H+
NCCOEEtN CO2HN"COEtCOPh H
COPh
43 44 7
Figure 14. Intramolecular Michael reaction as a key step in the synthesis of kainoids
1.4.2 Modification of an existing pyrrolidine ring
Modification of an existing pyrrolidine ring has also been employed in kainoid
synthesis. Substituents have been introduced to pre-existing rings through a variety of
methods. Selected examples are described in the following.
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Ohfune and Tomita have employed a Diels-Alder reaction to introduce the C3 and
C4 substituents to the pyrrolidine ring. 32 The key intermediate 45 (Figure 15), prepared
from pyroglutamic acid, was reacted with 2-(trimethylsilyl)oxy-l,3-pentadiene to give a
single adduct, lactam 46 with the desired facial selectivity in a stereospecific process via
[4+2] cycloaddition. The lactam 46 was elaborated to (-)-domoic acid (Figure 2, 13) in a
number of steps.
TMSO
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Figure 15. Diels-Alder reaction as a key step in the synthesis of kainoids
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Figure 16. Intromolecular radical cyclization as a key step in the synthesis of kainoids
26
An intramolecular radical cyclization has been employed to introduce the C3
substituent to the pyrrolidine ring in the synthesis of acromelic acid analogs 52-55,4 as
illustrated in Figure 16. Radical cyclization of bromoacetal 48, prepared from trans-4-
hydroxyl-L-proline 47, followed by epimerization of the C2 substituent using DBU in hot
toluene and lactol oxidation, afforded the bicycle 49, which was elaborated to tosylate 50.
A displacement of tosylate 50 by various lithium diaryl cuprates with retention of
configuration at C4 position followed by esterification of the C-2 carboxylic acid
furnished pyrrolidine 51, which was then elaborated to the kainoid analogs 52-55.
A Michael addition has been used to introduce C4 substituent in the synthesis of
kainoid analog CPPA (Figure 2, 7).133 Shown in Figure 17, the key step is a
stereocontrolled Michael addition of appropriate nucleophiles such as dimethyl
sodiomalonate to the pyrrolidone 56, affording the Michael adduct 57 in 85% yield,
which was transformed to the kainoid analog CPAA (Figure 2, 7) in several steps
including decarboxylation, reduction, deprotection, Jones oxidation and basic hydrolysis.
1.5 Objective of research
Kainic acid (Figure 1, 4) is a research tool mostly used by neuroscientists for the
study of glutamate receptors such as kainate receptors. The study of kainate receptors
helps researchers to understand Alzheimer's disease, epilepsy, and other brain disorders.
Kainic acid (Figure 1, 4) is extracted from a red seaweed of the genus Digenea, which
can be found in many tropical and subtropical waters. The alga containing the highest
concentrations of kainic acid is Digenea simplex, known to grow only in disputed waters
in the South China Sea. It is claimed that in some Digenea, the concentration can be as
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high as 276mg per 1 Og of dry weight. The use of Digenea simplex is practically
essential to achieve the commercially viable extraction of pure kainic acid. All efforts to
synthesize this compound in a commercially viable way have failed. For a while, the only
source was a Taiwanese company that extracted kainic acid from Digenea simplex.
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Figure 17. Michael addition as a key step in the synthesis of kainoids
However, several years ago, the world's sole supplier of kainic acid discontinued this
product, hampering the neuroscience research.134 Although some alternative sources have
been available, the prices of kainic acid are still significantly higher than once it was.135
Numerous syntheses of kainoids have been published,136 however none have proven to be
simple and practical. This is largely due to the synthetic challenge arising from the
typical kainoid skeleton containing three contiguous stereocenters in a trans (C2-C3), cis
(C3-C4) arrangements around the pyrrolidine ring. 136, 137 The above observation
prompted us to search for a less costly but still potent alternative to kainic acid. We
envisaged that the aza anolog of kainic acid 58 (Figure 18) would be a good substitute for
kainic acid as the probe in the study of glutamate receptors due to its structural similarity
to kainic acid and theoretically much simpler synthetic accessibility compared with
kainic acid (see Section 1-7). Molecular modeling studies showed that 58 fits well in the
kainate receptor. Similarly, the aza analogs of kainoids 59 and 60 would also be good
substitutes for the kainoids 23 (Figure 4) and 7 (Figure 2) respectively.
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The purpose of this dissertation is thus to design and to synthesize aza analogs of
kainic acid, which would be good substitutes for the corresponding kainoids in the study
of glutamate receptors and which could be synthesized more easily compared to the
corresponding kainoids. The targets are aza analogs of kainoids 58-60 (Figure 18), which
have the same structure as their corresponding kainoids except that the methylene group
at the 5 position in the kainoids is replaced by an NH group. Such compounds should
still be potent agonists at kainate receptors as supported by modeling studies described in
Section 1.6 and they should be more synthetically accessible than their kainoid
counterparts as discussed in Section 1.7. I attempted to synthesize these aza analogs of
kainoids via a 1, 3-dipolar cycloaddition followed by reduction of the resulting
cycloadducts and functional group transformations.
1.6 Modeling study of aza analog of kainoids 58 in kainate receptor GluR6
The design of selective agonists has, until recently, been hampered by the lack of
a three-dimensional model of iGluRs. Early computer models, which were ultimately
found to predict the structure of the ligand binding core with remarkable accuracy,13 8
were based on homologies between iGluRs and bacterial glutamine binding proteins
(QBP), and lysine/arginine/omithine binding proteins (LAOBP). 91'139' 140 Later, these
models were supported by site-directed mutagenisis experiments 141-144 and, more recently,
by the acquisition of crystal structures (Section 1.3).
The resolution of a three-dimensional model for the ligand binding core of iGluR2,
iGluR5 and iGluR6 co-crystallized with several ligands and in various stages of closure
not only provided a tremendous advance in our understanding of the mechanism of ligand
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binding and gating of ionotropic glutamate receptors (See Section 1-3), but will no doubt
prove to be a tremendous advantage in the structure-based design of ligands of
pharmacological interest in the study of many neurological disorders. Molecular
modeling study of the aza analog of kainoids 58 in the ligand binding core of iGluR6,
when co-crystalized with domoic acid (PDB Id: 1YAE) suggests that it would be a good
substitute for u-kainic acid as an agonist at kainate receptors.
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Figure 18. Some kainoids and aza analogs of kainoids
Low-mode conformational search (LMCS) addresses the complex problem of
docking a flexible ligand into a flexible receptor. 145,146 The LMCS method consists of a
Monte Carlo (MC) step in which the atoms in the freely flexible parts of the structure are
moved along a trajectory that is consistent with the low frequency normal modes of
vibration for that part of the structure. In low-mode docking searches, ligands are
additionally subject to explicit translations and rotations. Thus conformational,
orientational and positional space is sampled. Each Monte Carlo step is followed by
energy minimization (EM) of the geometrically perturbed structure. A comparison of the
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ability of commonly used computational methods (Catalyst, Confort, Flo99, Macromodel
and Omega) to reproduce protein-ligand assemblies has determined that the low-mode
conformational search algorithm (using the AMBER force field with GB/SA solvation)
as implemented by Macromodel was superior to all other methods examined. 1 47
Carcache et al. reported the low-mode docking caclulations of the kainic acid analogs,
domoic acid and isodomoic acids, in the iGluR2 receptor. 148 Remarkably, this method
was able to accurately predict the relative stabilities of a series of structurally related
ligands with only slight variations in relative binding affinities. The low-mode docking
search in iGluR homology model149 identified three critical residues of ionotropic
glutamate receptors that strongly influence ligand selectivity, Leu65O, Thr649, and
Leu704. The latter two residues have not previously been implicated in ligand selectivity.
To show that aza analog of kainoids 58 would be a good agonist at kainate
receptors, low-mode docking searches of 58 in the ligand binding core of iGluR6 when
cocrystallized with domoic acid (Figure 2, 13) (PDB Id: 1 YAE) were undertaken. As one
would anticipate, these calculations indicate that aza analog 58 is able to adopt a
geometry that resembles the conformation of kainic acid identified in the crystal structure
(PDB Id: 1TT1) and allows it to bridge the two domains when docked in the iGluR6 via
interactions between the receptor and compound 58 that are similar to those between
kainic acid and the receptor identified in the crystal structure. The results of the
calculations are summarized in the following.
Five-membered rings may occupy one of two conformations (Figure 19), the
envelope (E) and the twist (T). Each atom may assume any position in the various
conformations. Thus ten envelopes and ten twists, along with intermediate geometries
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along the pseudorotational path, are available to kainoids. The conformation of kainic
acid within the ligand binding core of iGluR6 (PDB Id: iTT1) corresponds to E3 .98 This
structure served as the starting geometry for low-mode docking searches of aza analog of
kainoids 58 in iGluR6. Since compound 58 may have two different ionic structures 58a
and 58b which differ in the nitrogen on the ring that is protonated (Figure 19) (to avoid
confusion we use the same numbering system for pyrazolidines throughout this
dissertation as is used for kainoids, even though it is not the correct system for
pyrazolidines), the low-mode docking searches of 58a and 58b in iGluR6 were both
carried out.
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Figure 19. Envelop (E) and half-chair (T) conformations of cyclopentane. Two ionic
structures of aza-KA 58. View of the E4 conformation of aza-KA 58. The
subscript refers to the out of plane atom.
A LMCS/MOLS search of aza analog of kainoids 58 in ionic form 58a in the
ligand binding core of iGluR6 SlS2 was performed. The receptor was represented as a
fixed shell within which various orientations and conformations of 58a were sampled.
Eight structures within a 25 kJ/mol energetic window (Table 1) were identified for 58a.
These eight structures represented three ring conformations: E4 , E5 , and El, represented
four, two and two times. The RMS for superposition of the five ring atoms on the kainic
acid crystal structure, as well as the comparison of the side chain orientation, reveal that
the global minimum structure 1 (Table 1, entry 1) corresponds closely to that of kainic
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acid bound to iGluR6. Important hydrogen bonding interactions similar to those
identified in the kainic acid crystal structure are observed in this structure. The hydrogen
bonding interactions between the ligands and receptor are summarized in Table 2 and
shown in Figure 20a-20c. Although no hydrogen bond from the y-carboxylate of 58a to
Thr690 (domain 2), compared to the kainic acid crystal structure (Figure 20a), is present
in the global minimum structure of 58a identified in the docking calculation (Figure 20b),
it is compensated for by a hydrogen bond to Lys 762 (domain 2). Thus 58a is able to
maintain important domain bridging interactions in iGluR6.
Table 1. Conformations of aza-KA 58a in the iGluR6 receptor
Entry Conf. RMSa (A) Relative energy C3-4-l'-2'
(kcal / mol) dihedral angle
(crystal = 124.8")
1 E4  0.178 0 120.9
2 El 0.243 3.29 103.2
3 E4  0.169 3.49 117.8
4 E1  0.236 4.69 -103.6
5 E4  0.172 4.89 -33.7
6 E4  0.178 5.14 -98.7
7 E5  0.245 5.53 104.7
8 E5  0.239 5.89 115.3
aFor superposition of the five ring atoms on the kainic acid crystal structure conformation.
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Table 2. Hydrogen bonding interactions between ligands and iGluR6 receptor
Amino acid KA in iGluR6 Aza-KA 58a Aza-KA 58b
residues in iGluR6 (PDB Id: ITT1) docked in iGluR6 docked in iGluR6
receptor
Arg523 (domain 1) guanidinium NH to guanidium NH to guanidiniu NH to
the a-carboxylate of the a-carboxylate of the c-carboxylate
KA 58a of 58b
Arg523 (domain 1) guanidinium NH2 to guanidinium NH2
the o-carboxylate of to the a-
KA carboxylate of 58b
Ala518 (domain 1) NH to the a- NH to the a-
carboxylate of KA carboxylate of 58a
Pro516 (domain 1) carbonyl oxygen to carbonyl oxygen to carbonyl oxygen to
NH of KA N(1)H of 58a N(5)H of 58b
G1u738 (domain 2) y-carboxylate to NH y-carboxylate to
of KA N(1)H of 58a
G1u738 (domain 2) y-carboxylate to y-carboxylate to
N(5)H of 58a N(5)H of 58b
Ala689 (domain 2) NH to the a- NH to the a- NH to the a-
carboxylate of KA carboxylate of 58a carboxylate of 58b
Thr690 (domain 2) NH to the y-
carboxylate of KA
Lys762 (domain 2) &-NH2 to the y- c-NH2 to the y-
carboxylate of 58a carboxylate of 58b
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Figure 20a. Kainic acid in the iGluR6 S 1 S2 receptor (part of crystal structure with water
molecules excluded for simplicity, PDB Id: ITT 1). Dashed purple lines represent
hydrogen bonds within the receptor. Green lines represent hydrogen bonds between the
ligand and receptor.
Figure 20b. Global minimum conformation of aza analog 58 in ionic form 58a in the
iGluR6 Si S2 receptor. Dashed purple lines represent hydrogen bonds within the receptor.
Green lines represent hydrogen bonds between the ligand and receptor.
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Figure 20c. Global minimum conformations of aza analog 58 in ionic form 58b in the
iGluR6 S 1 S2 receptor. Dashed purple lines represent hydrogen bonds within the receptor.
Green lines represent hydrogen bonds between the ligand and receptor.
Within a 25 kJ/mol energetic window, fourteen geometries are available to
compound 58b with N5 protonated (Table 3). These fourteen structures represented three
ring conformations: E4, E5, and E1, represented six, five, and three times. The RMS for
superposition of the five ring atoms on the crystal structure, the comparison of the side
chain orientation, as well as the consideration of the relative energy, suggest that the
global minimum structure 1 corresponds closely to that of kainic acid bound to iGluR6.
Similar hydrogen bonding interactions to those identified in the kainic acid crystal
structure are also observed in this structure (Table 2, Figure 20c). This structure forms
hydrogen bonds between the u-carboxylate and Arg523 (guanidium NH), between the ac-
carboxylate and Arg523 (guanidium NH2), between N5H and Pro516 (carbonyl oxygen)
on domain 1, and between N5H and Glu 738 (y-carboxylate), between the a-carboxylate
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and Ala689 (NH), between the y-carboxylate and Lys762 (E-NH 2) on domain 2. These
hydrogen bonding interactions are maintained from structure 1 to structure 3. In structure
3, additional hydrogen bond from N1H to Glu738 (y-carboxylate) is present. Thus, 58b is
also able to maintain the important domain spanning interactions which are critical to the
domain closure of iGluR6.
Table 3, Conformations of aza-KA 58b in the iGluR 6 receptor
Entry Conf. RMSa (A) Relative energy C3-4-l'-2'
(kcal / mol) dihedral angle
(crystal = 124.80)
1 E4  0.186 0 116.9
2 E 4  0.184 1.50 -24.7
3 E4  0.168 1.89 117.5
4 E4  0.164 2.16 -121.5
5 E1  0.236 3.25 106.0
6 E4  0.167 3.28 -25.9
7 E4  0.174 4.21 -97.2
8 Es 0.254 4.44 115.1
9 Es 0.265 4.76 105.3
10 E5  0.222 4.78 -101.8
11 E 0.233 4.87 -101.3
12 E5  0.239 5.36 107.3
13 ES 0.231 5.37 114.7
14 E1  0.258 5.39 103.3
aFor superposition of the five ring atoms on the kainic acid crystal structure conformation.
Docking energies are compared for the global minima of 58a and 58b in Table 4,
which suggests that 58b has slightly higher binding affinity than 58a at iGluR6. Docking
energies were estimated as the energy difference between the energy (Einside) calculated
for the receptor-ligand complex when the ligand is bound to the receptor in its global
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minimum energy conformation and orientation, and the sum of the energies (Eotside)
calculated for the separated ligand (in its bound global minimum energy conformation)
and the receptor, to be specific, docking energy = (Eoutside - Einside).
Table 4. Estimated relative docking energies for 58a and 58b
Agonist Relative docking energy (kcal/mol)
58a 0
58b 0.52
In conclusion, the aza analog of kainoids 58 can have interactions with the iGluR6
receptors similar to those between kainic acid and iGluR6 to achieve the domain closure
and thus may be as potent as kainic acid at kainate receptors.
1.7 Research design
As shown in Figure 21, the skeleton of aza analogs of kainoids (pyrazolidines)
can be constructed via the 1, 3-dipolar cycloaddition of the appropriate diazoalkane
(diazoacetone,150 henyldiazomethane,151 and diazomethane respectively) and the
dipolarophile diethyl glutaconate followed by the reduction of the resultant cycloadducts
(1-pyrazolines). The relative configuration in the aza analogs of kainoids is highly
predictable in the cycloaddition based on the consideration of the stereochemistry in the 1
3-dipolar cycloaddition of diazoalkanes and alkenes, When an c, P-unsaturated ester such
as trans diethyl glutaconate is used as the dipolarophile, the regioselectivity will be such
that the terminal nitrogen of the diazoalkane will be connected with the cc-carbon of the
ester due to diazoalkane HOMO- dipolarophile LUMO interactions (Figure 22).152
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Figure 21. Retrosynthetic analysis of aza analogs of kainoids
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a. Reduction of2-pyrazolines
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Figure 22. Proposed synthesis of aza analogs of kainoids
However, some exceptions have also been observed.153 ,154 The relative configuration of
the dipolarophile will be retained in the cycloadduct since the cycloaddition is
stereospecific and syn with respect to the dipolarophile. Depending on the nature of the
substituents, the cycloadduct containing either trans or cis relative configuration between
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the substituents at the 4 and 5 positions of the 1-pyrazoline ring may be obtained (to
avoid confusion we use the numbering system for pyrazolines shown in Figure 21
throughout this dissertation). The cis relative configuration will be favored if there may
be 7t interactions between those two substituents in the transition state.155 Therefore the 1,
3-dipolar cycloaddition of trans diethyl glutaconate with diazoalkanes will produce the
appropriate 3, 4-trans, 4, 5-cis relative configurations in the cycloadduct if the
cycloaddition follows the expected course. The reduction of the 1-pyrazolines will yield
61, 62 and 63, respectively (route b, Figure 22). Hydrolysis of 62 and 63 will give the
desired targets 59 and 60 (Figure 18), respectively. Conversion of 61 to the target 58 will
be achieved after functional group transformations.
R1 R1
Ne XO H N\ X
NN
0 0
1-pyrazolines 2-pyrazolines
Figure 23. Isomarization of 1 -pyrazoline
However, prior studies on the cycloadditions of diazoalkanes with o, p-
unsaturated esters have shown that the 1-pyrazolines initially formed in such
cycloadditions readily isomerized to the corresponding conjugated 2-pyrazolines (Figure
23).153,156 Therefore, it is possible that 1-pyrazolines formed in the cycloadditions of
diazoalkanes with trans diethyl glutaconate will isomerize to the 2-pyrazolines with the
direction of double bond isomerization dependent on the substituents (Figure 22),
resulting in the loss of one of the newly formed stereocenters. If this is the case, aza
analogs 61, 62 and 63 (Figure 22) will be obtained after the selective reduction of C=N
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double bond in the 2-pyrazolines, respectively (route a, Figure 22). Thus this research
would provide the easy access to the aza analogs of kainoids which are potentially potent
alternative to the corresponding kainoids.
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2. Results and Discussion
2.1 1,3-Dipolar cycloadditions between diazoalkanes and trans-diethyl glutaconate
The dipolar cycloadditions of diazoalkanes with trans-diethyl glutaconate have
been evaluated and the results are summarized in Table 5 and Figure 24. Some 2-
pyrazolines 64b, 65a, 65b, 66a (Figure 24) have been obtained in good yields and were
converted to Cbz derivatives to prevent oxidation.
Table 5. 1, 3-Dipolar Cycloaddition of Diazoalkanes and trans Diethyl glutaconate
#eq.
R RCHN2  Conditions Yielda Product ratio
____ _a:b
H 2.2 Et2O, 23 C, 15 hr. 90% 0:100'
Ph 0.9 THF, -78 C-23 C, 15 hr. 73% 80:20'
CO 2Et 1.2 C6H6, reflux, 72hr. 39% 13.5:0:1(66a:66b:68)
1.2 PhCH3, reflux, 72hr. 37% 4:0:1 (66a:66b:68)
2 C6H6, reflux, 72hr. 64% 3 :0:1 (66a:66b:68)
" 2 PhCH3, reflux, 72hr. 89% 3-0:1(66a:66b:68)
TMS 6 PhCH 3/hexane, 23 C, 3 d. 58% 1.7:1
( 9 6 %b)
TMS 2 C6H6/hexane, reflux, 8.5h; 5 1% 1:1.4d (69c:69d)
1.1 eq. CbzCl,
1.leq. NaHCO 3,
1:1 CH 2Cl2/ H 20
TMS 3 C6H/hexane, reflux, 8.5h; 2 4 % 1:5 (69e:691)
I0eq. EtO2COCl,
2eq.AgOTf, CH 2 Cl2
Pu-ified bBased on recovered diethyiglutaconate
Deteined by NMR d Based on isolated yield
eRegioisomers were not specifically assigned. Two-step overall yield
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a) See Table 5 for conditions and yields. b) Cbz-chloride, CH 2C12, Na2CO 3(aq.) c) N2CHCO2Et/L
Figure 24. 1,3-Dipolar cycloadditions between diazoalkanes and trans-diethyl glutaconate
The 1-pyrazolines either isomerized to the 2-pyrazolines or became oxidized to
the pyrazoles. Because of the tendency of the 2-pyrazolines to become oxidized (phenyl
substituted pyrazolines in particular), they were converted to the Cbz derivatives, which
tends to inhibit oxidation, for full characterization.
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The cycloaddition of diazomethane and trans-diethyl glutaconate yielded, as
expected, a single 2-pyrazoline product (64b) in 90% yield at ambient temperature under
nitrogen after 15h. 64b was obtained in relatively high purity from the cycloaddition and
can be used for further transformation without purification. It was found that this
cycloaddition was completed in less than 2 hours. Although it is not stable on standing,
the zH NMR, 'C NMR, COSY, APCI mass spectrum of 64b were able to be acquired to
help assign its structure. After the cycloaddition immediately followed by treatment with
CbzCl (1.l eq.) in the presence of NaHCO3, 64b was converted to its Cbz derivative 64d
in 93% yield and no formation of oxidation product of 64b or its Cbz derivative 70 was
observed based on the crude 1H NMR spectra of 64b and 64d. In this case, the crude 64d
was of sufficient purity to allow its use in subsequent reactions without further
purification. However, when 64b was treated with CbzCl after it stood at ambient
temperature for 3 days, its Cbz derivative 64d was obtained in 48% yield along with the
Cbz derivative of its oxidation product, 70, in 13% yield.
The reduction of the C=N double bond of 64b or 64d is required to furnish the
target aza analog of kainoids 60 (Figure 18). Since the Cbz group can not survive some
reducing conditions such as catalytic hydrogenation and reduction with lithium aluminum
hydride, 64b was also protected as other derivatives shown in Figure 25. 64b was
converted to the carbamate 71 in 74% yield by treatment with ClCO 2Et in CH 3CN mixed
with aqueous saturated K 2C0 3 solution.15 7 By treatment of 64b with PhCOCl in the
presence of NaHCO 3 in 1:1 ratio of H20 and THF, the amide 72 was obtained in 98%
yield.158 By treatment of 64b with CH 3COCl in the presence of NaHCO3 in 1:1 ratio of
H2 0 and THF, the amide 73 was obtained in 92% yield.
158 Attempt to prepare the N-
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sulfonyl derivative of 64b was not successful by treatment of 64b with 1.5eq. p-
toluenesulfonyl chloride'59 in methylene chloride in the presence of 1.5eq. imidazole and
1.5eq. triethylamine at room temperature for 3 days.
O
HN/ OEt
N
O
64b
a b Oc O
OEt O OEt Q Et
EtO2C-N, / OEt NN / OEt N OEtN OPh N2 Me N
7 720 73 00 71
74% yield 98% yield 92% yield
Conditions: (a) 2eq. CICO 2Et, Aqueous Sat. K2C0 3, CH 3CN.
(b) 1.leq. CH 3COCI, 2eq. NaHCO 3,1:1 H20/THF
(c) 1.leq. PhCOCl, 2eq. NaHCO3, 1:1 H2O/THF
Figure 25. Protection of 2-pyrazoline 64b
The cycloaddition of phenyldiazomethane15 1 and trans diethyl glutaconate
conducted in dry THF overnight under nitrogen yielded two 2-pyrazoline adducts (65a
and 65b) in a ratio of 4:1 as indicated by crude 'H NMR spectrum and an overall isolated
yield of 73%. On standing, this mixture readily oxidizes to a single pyrazole (67)
confirming that 65a and 65b are not regioisomers with respect to the cycloaddition. Upon
treatment of the mixture of 65a and 65b with CbzCl, their Cbz derivatives 65c and 65d
were obtained in 68% and 56% yield, respectively. The double bond regioisomers (65a
and 65b and their Cbz derivatives) are readily distinguished on the basis of 13C and 'H
NMR. The relative configuration of the 3, 4-substituents of 65a is expected to be trans
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and is confirmed by the similarity of the 'H NMR to similarly substituted 2-
pyrazolines153 and [4, 5]-dehydropyrrolidines 60' 161 in terms of the vicinal coupling
constant. The relative configuration of the 4, 5- substituents of 65b is assigned as cis on
the basis of NOESY spectrum of its Cbz derivative 65d, the vicinal coupling constant (12
Hz)160 and the large upfield shift of one of the diastereotopic C4 side-chain methylene
protons (62.12 ppm and 62.09 ppm) for 65b and 65d, respectively compared to a range
from 6 2.51ppm to 6 2.95ppm for 64d, 65a, 65c, 66a and 66c. This large upfield shift,
due to shielding of the C4 side-chain methylene, is consistent with 3, 4-cis substituted
kainoids with an aromatic ring at the 4-position160, 161 and is also consistent with a recent
empirical analysis of NMR data of various natural and synthetic kainoids.162 The trans
isomer of 65b was not observed, suggesting that the relative stereoselectivity of the
cycloaddition is cis.
Ethyldiazoacetate was unreactive at room temperature due to the electron
withdrawing effect of the carbonyl. Thus the cycloaddition was carried out in refluxing
benzene or toluene providing the trans isomer 66a, along with a by-product 68, which
arose from carbene insertion into the N-H bond of the 2-pyrazoline 66a. Assignment of
relative configurations of 66a was based on coupling constants of the ring protons160 and
NOESY spectrum of its Cbz derivative 66c. Assignment of relative configurations of 68
was confirmed by conversion of 66a to 68 by treatment with ethyldiazoacetate. When
66a was reacted with 2eq. ethyldiazoacetate in refluxing toluene for 72h, 68 was obtained
in 16% yield. The use of two equivalents of ethyldiazoacetate in refluxing toluene or
benzene improved the overall cycloaddition yield, but also increased the proportion of the
by-product 68. Failure to identify the cis product 66b suggests either that the preferred
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stereoselectivity of the cycloaddition is trans or that the double bond isomerization is
regioselective toward a cis substituted carbonyl group, by virtue of the relief of torsional
strain which would be present in a 3, 4-cis substituted 1-pyrazoline intermediate.
Attempts to improve the yield by extending the reaction time (up to 10 days) or
increasing the amount of ethyldiazoacetate (up to 3eq.) were not successful.
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Figure 26. Preparation of some pyrazolidine compounds starting from TMSCHN 2
It was reported that the cycloaddition of trimethylsilyldiazomethane and chiral
acrylamides produced 2-pyrazoline 74 (Figure 26) via proteodesilylation163-165 which was
reduced to the pyrazolidine compound 75 (Figure 26) upon treatment with sodium
cyanoborohydride in acetic acid]63 or were converted to the pyrazolidine compounds 76
(Figure 26) with a new subtituent being introduced at C4 position around the
pyrazolidine ring via Lewis acid promoted addition of some nucleophiles to the C=N
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bond of the 2-pyrazolines16 6 (Figure 26). It was envisaged that this strategy can be
applied towards the synthesis of aza analogs of kainoids such as the target compound 60
(Figure 18). Thus, the reaction between trans-diethyl glutaconate and
trimethylsilyldiazomethane was carried out in the hope of obtaining the 2-pyrazoline 64a
(Figure 24) which contains no subtituent at C-4 position around the pyrazoline ring.
However, the cycloaddition conducted in the mixture of toluene and hexane at room
temperature for 3 days, failed to provide 2-pyrazolines. Instead, a mixture of pyrazoles
(69a and 69b) (Figure 24) in a ratio of 1.7:1 (Table 5) was obtained. Apparently, the
regioselectivity of the cycloaddition is partially reversed as the size of R increases and
steric effects overcome electronic effects. The desired protected 2-pyrazoline 69d (Figure
24) was obtained in 30% yield along with the TMS retained 2-pyrazoline 69c (Figure 24)
containing an isolated C=N double bond in 21% yield when trans-diethyl glutaconate
was treated with 2eq. trimethylsilyldiazomethane in refluxing benzene and hexane
mixture for 8.5h followed by the treatment of the crude cycloadduct mixture with CbzCl.
Treatment of the crude cycloadduct mixture with 1 Oeq. ethyl chlorofomate and 2eq.
AgOTf in methylene chloride at room temperature did not exclusively afford the
protected desilylated product 69f (Figure 24) as expected 6 4, 165 although it significantly
increased the proportion of the desilylated product. In this case, the protected desilylated
product 69f (Figure 24) was obtained in 20% yield along with the silylated product 69e
(Figure 24) in 4% yield, in which the C=N double bond is conjugated to the ester group.
The relative configuration of the 4, 5-substituents of 69e was tentatively assigned as trans
based on the vicinal coupling constant (5.6Hz). The above observations that the same
cycloaddition gave rise to different products under different conditions aroused our
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interest in the reactivity of trimethylsilyldiazomethane in the 1, 3-dipolar cycloaddtion
with different diploraphiles. We then carried out a systematic survey of dipolar
cycloadditions between TMS diazomethane and a, j-unsaturated dipolarophiles. This
work will be described in Section 2.3. The reduction of the protected 2-pyrazoline 69f to
yield the corresponding pyrazolidine compound will be described in Section 2.2.2.
Bz H
N N Lewis Acid HN
EtO H CH2C1 2  EtO H
0 O*C, 20h 0
77 78 46-93%
79
PhCH=N-NHTs + QEt BF3.OEt2 (14equiv.)EtO No cycloaddition occurred.
0
Figure 27. Cycloaddition of hydrazones with olefins
Kobayashi et al reported that the cycloaddition of hydrazone 77 with olefin 78
was achieved to afford the pyrazolidine 79 in the presence of BF 3.OEt2 or a catalytic
amount of Zr(OTf)4, Hf(OTf)4, or Sc(OTf) 3 under mild conditions (Figure 27).167 The
easy construction of the pyrazolidine ring in these cycloaddtions drew our attention and
prompted us to explore the possibility of applying this strategy in the synthesis of our
target compounds. Unfortunately, no reaction of tosylhydrazone with diethyl glutaconate
(3eq.) occurred in the presence of 1.4eq. BF3.OEt2 at room temperature for 24h. The
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same thing happened when tosylhydrazone was treated with 3eq. diethyl glutaconate in
the presence of 1.4eq. BF 3.OEt 2 in refluxing methylene chloride for 5 days. When the
reaction was conducted in refluxing benzene for 42h, no formation of the cycloadduct
was observed and diethyl glutaconate was recovered with tosylhydrazone being
converted to the intractable materials possibly due to its decomposition at the reaction
temperature based on the crude 1H NMR.
2.2 Reductions of 2pyrazolines
The dipolar cycloadditon of diazoalkanes and trans-diethylglutaconate provides
the appropriate pyrazoline ring which may be converted into aza analogs of kainoids via
reduction. Reductions of the 2-pyrazolines and their Cbz derivatives have been carried
out and the results are summarized in the following.
2.2.1 Reductions of unprotected 2-pyrazolines 64b, 65a and 65b
When 64b (Figure 24) was treated by NaBH 4168-170 in ethanol overnight, no
formation of the corresponding pyrazolidine compound was observed based on the crude
H NMR and mass spectrum. Low mass balance was obtained from this reaction. The
reduction of the imine C=N double bond of 64b (Figure 24) was not effected when 64b
(Figure 24) was treated by H2 (1ati or ~50psi) in the presence of Pd160, 171 on activated
carbon in Et 2O or EtOH or in the presence of Raney Ni72 in EtOH respectively. Most of
64b (Figure 24) was recovered along with some intractable materials in these reactions.
When the mixture of 65a and 65b (Figure 24) was treated with NaBH 4 in EtOH,
NaBCNH 3 in EtOH173 , H2 (55 psi)/Pd on 10% charcoal in EtOH, H2 (55 psi) /Pd on
activated carbon in EtOH, at room temperature, respectively, no reduction of the C=N
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bond in 65a and 65b (Figure 24) was observed and the oxidation product 67 (Figure 24)
was obtained in the yield of 8%, 8%, 8%, 6%, respectively along with intractable
materials. The reduction of the unprotected 2-pyrazoline was thus not pursued further due
to their potential oxidation to the corresponding pyrazoles.
2.2.2 Reductions of protected 2-pyrazolines
When 65c and 65d (Figure 24) were treated with H2 (latm) in the presence of
palladium on activated carbon in EtOH at room temperature, the removal of Cbz group
was effected to yield the unprotected 2-pyrazolines 65a and 65b (Figure 24), but no
reduction of the C=N bond was observed. The application of higher pressure of H2 (55psi)
to the reaction yielded only intractable materials. Treatment of 65c and 65d with 0.5eq.
lithium borohydride161'174 in dry THF at ambient temperature for 30h yielded the
intractable materials with 12% of the starting material being recovered. When 1.8eq.
superhydridel 5 7 was used to treat 65c and 65d (Figure 24) in dry THE at room
temperature for 65h, intractable materials were obtained along with some recovered
starting material.
Due to the aforementioned failure of the reduction of the C=N double bond of
65c and 65d (Figure 24), our attention was turned to the reduction of the C=N double
bond of 64d (Figure 24) as a model system for the reduction as it is more easily
synthesized compared to 65c and 65d (Figure 24). Many reducing agents that have been
reported to be capable of reducing an imine C=N double bond have been used to treat
64d (Figure 24). Unfortunately, no such reduction has been achieved. The results of
these reductions are summarized in Table 6.
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Figure 28. Some products obtained from the reduction of 64d
Table 6. Reduction of 64d
Entry Reducing agent Conditions Results
1 NaCNBH 3 (2.5eq.) CH 3COOH, R.T. Most of the starting
(1) 1.5 hrs or (2) 17h material was recovered.
2 NaCNBH 3 (10eq.) p-toluenesulfonic acid, 1:1 No reaction
DMF-dioxane, reflux, 22h
3 NaBH 4(2.5 eq.) EtlOH, R.T., 15h Probably 80 (Figure 28)
was formed
4 NaBH 4(2.5 eq.) EtOH, reflux, 15h intractable materials
5 NaBH 4(2.5 eq.) AcOH, R.T., 18h No reaction
6 NaBH 4(10eq.) AcOH, R.T., 1.5h; No reaction
Reflux, 3h; R.T., 15.5h
7 NaBH 4(leq.), MeOH, 0 0C, 5h, 81 (Figure 28)
CeCl 3(leq.) then R.T. , 12h (55% yield)
8 NaBCNH 3 (2.5eq.), EtOH, R.T., 17h No reaction
CeCl 3 (leq.)
9 LiBH4(0.75 eq.) THF, R.T., 24h Complicated mixture
10 LiAlH4(3eq.) THF, R.T., 22h; then Complicated mixture
reflux, 6h
11 B1 3(1.1 eq.), (1) THF, -78 C, 2h; or Most of the starting
phthalic acid (1.1 (2) THF, R.T., 19h. material was recovered.
eq.)
12 BH 3(0.4 eq.) THF, -78 C, 5h; then Complicated mixture
-78 C to R.T., overnight
11 SmI 2(2.5eq.), THF, R.T., <10s Intractable materials and
Et3N(5eq.) Low mass balance
H2 0(6.25eq.)
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14 SmI2(2.5eq.), THF, -78*C, 2h; then Nothing changed after 2h
Et 3N(5eq.) another 2.5eq SmI 2, -78*C at -78*C. Intractable
H20(6.25eq.) to R.T., overnight. materials were obtained.
The mass balance is low
(11%).
15 SmI 2(2.5eq.) THF, R.T., 22h The starting material was
not completely consumed.
A complicated mixture was
obtained.
16 H2 (50psi), EtOH, R.T., 18h Cbz group was removed.
Pd on activated A complicated mixture was
carbon obtained.
17 Mg (10 eq.) MeOH, R.T., 5h A complicated mixture
18 Et 3SiH(2eq.) Refluxing CF 3COOH Removal of Cbz group and
5h intractable materials
19 Me2NH.BH3(leq.) Gaseous HCl, PhCH 3  No reaction and the
R.T., 20h starting material was
recovered.
20 Me2NH.BH 3(1.6eq.) p-toluenesulfonic acid No reduction product was
(6eq.), CH 2Cl 2+MeOH, obtained and some starting
0 C material was recovered.
2h; R.T., 15h
21 Me2NH.BH 3(1{eq.) p-toluenesulfonic acid No reaction occurred and
(6eq.), PhCH 3+MeOH, the starting material was
reflux, 21h recovered.
22 Me3N.BH3(leq.) Gaseous HCl, PhCH 3  No reaction occurred and
R.T., 17h the starting material was
recovered.
23 Bu 3SnH(Seq.) BF 3.OEt2(4eq.), CH 2Cl 2, No reaction occurred and
-78*C to R.T., 45h the starting material was
recovered.
24 Bu 3SnH(2.5eq.) BF 3.OEt2(6eq.), CH 2Cl 2, No reaction occurred and
R.T., 26h the starting material was
recovered.
25 Li B(C 2H5) 3H CH 2Cl 2, -78 C, 4.5h 84(Figure 29), 42% yield;
(1.l6eq) 85(Figure 29) was
probably produced.
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26 LiB(C 2H5)3H CH 2 C12, -78*C, 20min; 86(Figure 29), 16% yield.
(1.leq.) then another 0.6eq of 87 was observed.
LiB(C 2 H) 3H, -78 0C to
R.T., overnight. Followed
by treatment with
ClCO 2Et.
27 LiB(C 2Hs) 3H CH 2C12, -78*C, 4h; 80 (Figure 28), 84 and 85
(1.16eq.) -78*C to R.T., overnight. (Figure 29) were probably
formed.
28 LiB(C 2Hs)3 H CH 2 C12, R.T., 20h. 80 (Figure 28) and 85
(1.16eq.) (Figure 29) were probably
formed. Low mass balance
(36%)
29 LiB(C 2Hs) 3H CH 2Cl 2, -78 C, 5h 88 (Figure 29) was
(2.16eq.) probably formed.
30 LiB(C 2H5 )3H CH 2Cl 2, -78 C, 5h Complicated mixture
(3.16eq.)
31 LiB(C 2H5)3H CH 2C12, -78 C, 3h; Complicated mixture
(1.leq.) then another 1.1eq of
LiB(C 2H5)3H, -78 C, 3h.
32 LiB(C 2H5 )3H CH2Cl 2, -21*C, 3.5h; 80 (Figure 28) and 84
(1.1 eq.) then another 1.1 eq of (Figure 29) were probably
LiB(C 2H5 )3H, overnight. formed.
Compared to the normal imine C=N double bond, the C=N double bond of 64d
(Figure 24) is more robust as indicated by the fact that no reduction of 64d (Figure 24)
occurred and most of the starting material was recovered in the reduction attempts with
sodium cyanoborohydride in acetic acid 163, 173, 175, 176 (Table 6, Entry 1), sodium
cyanoborohydride in 1:1 ratio of dimethylformamide and dioxane in the presence of
0.6eq. p-toluenesulfonic acid monohydrate at reflux 177 (Table 6, Entry 2), sodium
borohydride in acetic acid at room temperature for 18h or 10eq. sodium borohydride in
acetic acid at reflux for 3h 1 76' 178, 179 (Table 6, Entry 5-6).
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Instead of the reduction of C=N bond of 64d (Figure 24), 64d was reduced to the
alcohol 80 (Figure 28) by sodium borohydride in EtOH at room temperature based on the
crude 1H NMR and mass spectrum in less than 50% crude yield (Table 6, Entry 3). When
the reaction was conducted in EtOH at reflux for 15h, 64d (Figure 24) was converted into
intractable materials (Table 6, Entry 4). When 64d (Figure 24) was treated with 1 eq.
sodium borohydride in methanol in the presence of leq. CeC13180 at 00C for 5h and then
at room temperature for 12h, the transesterification occurred to yield compound 81
(Figure 28) in 55% yield (Table 6, Entry 7) instead of the reduction of C=N bond of 64d,
indicating that the polarization of the ester group by CeCl 3 occurred and CeCl3 was
unable to polarize C=N bond of 64d to increase its reactivity towards the hydride attack.
However, 64d was recovered when sodium cyanoborohydride was used as the reducing
agent in ethyl alcohol in the presence of CeCl 3 at room temperature for 17h (Table 6,
Entry 8). The same thing happened when 64d was treated with 1.1 eq. BH 3 in dry THF in
the presence of 1.1 eq. phthalic acid (Table 6, Entry 11). A complicated mixture was
obtained when 64d was treated with 0.4eq. BH 3 in dry THF (Table 6, Entry 12)1 or
with 0.75eq. lithium borohydride in dry THF at room temperature for 24h (Table 6, Entry
9) or with 3eq. lithium aluminum hydride in dry THF at room temperature for 22h and
then at reflux for 6h (Table 6, Entry 10).
SmI 2 has been shown to successfully reduce various nitrogen functionality (nitro
group 185-188 imi5es 15'189, oximes185, hydrazones185, 190, isoxazoles 191 and azides1 92 . The
SmI 2-mediated reduction of imines has been shown to be instantaneous in the presence of
H20 and an amine in THF.193 However, SmI2-mediated reduction of the C=N double
bond of 64d was unsuccessful, resulting only in intractable materials (Table 6, Entry 13-
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14) or a complicated mixture (Table 6, Entry 15). A complicated mixture was obtained
when 64d was treated with 1 eq. Mg194 in methanol at room temperature for 5h (Table 6,
Entry 17). Treatment of 64d with H2 (55psi) in the presence of palladium on activated
carbon in EtOH at room temperature for 18h resulted in the removal of Cbz group and
yielded only a complicated mixture (Table 6, Entry 16). However, when the same
reducing system was applied to compound 71 (Figure 25) at room temperature for 6 days,
no reaction occurred and 71 (Figure 25) was recovered. No reduction of C=N bond of
compound 72 (Figure 25) was observed and some starting material was not consumed
based on TLC analysis, 1H NMR and mass spectrum when 72 (Figure 25) was treated
with H2 (55psi) in the presence of PtO2 (up to 30% of the weight of the starting
material)171,195 in EtOH at room temperature for 71h.
Reaction of 64d with 2eq. Et3SiH in refluxing trifluoroacetic acid160, 196 for 5h
resulted in the removal of the Cbz group and formation of intractable materials (Table 6,
Entry 18). When compound 71 (Figure 25) was treated with 2eq. Et3SiH in refluxing
trifluoroacetic acid for 23h, most of 71 (Figure 25) was recovered and no reduction of
C=N bond was observed based on TLC analysis, crude 1H NMR and mass spectrum. In
contract to the reports that the BF3-promoted hydrostannation of N-heteroatom-
substituted imines197 -199 such as hydrazones, oximes, nitrones, and N-sulfonyl imines
successfully resulted in the reduction of the C=N bond, 64d was recovered from
treatment with Bu 3SnH in the presence of freshly distilled BF3.OEt2 in dry
dichloromethane (Table 6, Entry 23-24). Amino-borane complexes have drawn the
attention of many synthetic organic chemists. Their stability, tolerance to acids, solubility
in many solvents and good reducing power have led to a number of laboratory and
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industrial applications. 200-22 One of the most important applications of amino-borane
complexes is the reduction of the C=N double bond to form C-N.200, Two
particularly interesting amino-borane complexes are dimethylamine-boron complex
(DMAB) and trimethylamine-boron complex (TMAB). These solid complexes are safe,
economical, and soluble in protic and aprotic solvents and have been shown to effectively
reduce hydrazones to hydrazines.20 6,2 07 These two amino-boron complexes were thus
applied to the reduction of the C=N double bond of 64d, a fully substituted hydrazone.
Unfortunately, no expected reduction of the C=N double bond of 64d has been realized
(Table 6, Entry 19-22).
Since superhydride (LiBEt3H) has been used to successfully reduce the C=N
double bond of 2-pyrazoline compound 82 to afford the pyrazolidine compound 83
(Figure 29),157 it was used to treat the protected 2-pyrazoline 64d and its related
compounds in the hope of realizing the reduction of C=N double bond of these
compounds. Treatment of 64d with 1.16eq. superhydride in dry methylene chloride at
-780 C for 4.5h (Figure 29) effected the selective reduction of the ester group conjugated
to the C=N bond of 64d to furnish the aldehyde 84 in 42% yield (Table 6, Entry 25). In
this reaction, another impure compound was also isolated in small amount in less than
6% yield and assigned to the structure 85 based on its 'H NMR and mass spectrum and
the observation that, as monitored by the 'H NMR and mass spectrum, it turned into the
starting 2-pyrazoline 64d after ca. 50 days possibly by undergoing slow oxidation in the
air.'5 7 This indicated that the reduction of C=N bond of 64d occurred to a modest extent
and superhydride prefers to reduce the ester group conjugated to the C=N bond rather
than the C=N double bond. Interestingly, when 64d was treated with 1.1 eq. superhydride
57
in dry methylene chloride at -78 C for 20min and then another 0.6eq. superhydride from -
78C to room temperature overnight, the ester group conjugated to the C=N bond of 64d
was reduced to the hydroxyl group. This was suggested by the isolation of compound 86
(Figure 29) in 16% yield starting from 64d after treatment of the crude reduction product
TBDMSO Ph TBDMSO Ph
N/ LiBEt3 H HN.N HNN
Boc Boc
82 83
O O
Et OEt
a N + Cbz-NN OEtCb'N CHO HN
H O
84 85
0
0~ OEt
OEt b Et + Cbz -NN OEt
Cbz-N/ / OEt Cbz'NN OCOOEt O
N N EtO
O 86 764d 8
CHO
Cbz-NIN CHO
88
Conditions: a: LiB(C 2H5)3 H (1 2eq), CH 2CI2 , -78oC, 4.5h
b: (1) LiB(C 2H5)3H (11eq), CH2CI2 , -78*C, 20min;
LiB(C 2H5)3H (0.6eq), CH2CI2 , -78 C-R.T., overnight.
(2) CICOOEt
c: LiB(C 2H5)3H (2.16eq), CH2CI2, -78*C, 5h
Figure 29. Reduction of 64d and 82 with superhydride
with ethyl chloroformate in saturated K 2C0 3 in acetonitrile, which was initially expected
to protect the possible reduction product 85 but did not succeed since 87 was not isolated.
Attempts to increase the yield of 84 (Figure 29) by increasing the number of the
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equivalents of superhydride, the reaction temperature, and/or the reaction time were not
successful (Table 6, Entry 27-32). Increasing the number of the equivalents of
superhydride and/or the reaction temperature results in the lower chemoselectivity in the
reduction. For example, treatment of 64d with 2.16eq. superhydride in dry methylene
chloride at -78 C for 5h (Table 6, Entry 29) probably afforded 88 (Figure 29) based on its
H NMR and mass spectrum, indicating the reduction of both ester groups.
Similar to 64d, the Cbz protected 2-pyrazoline 66c was reduced to the aldehyde
89 in 34% yield when it was treated with 1.1 eq. superhydride in methylene chloride at -
7 8 C fo r 5 h (F ig u re 3 0 ).
0 0
EtOOCOlEt OH Ot1.1eq. superhydride
OEt N\ OEt
Iz 0CH 2 CI2 , -78C, 5h
34% yield
66c 89
Figure 30. Reduction of 2-pyrazoline 66c with superhydride
It was felt that the conjugation between the electron-withdrawing carbonyl group
and the C=N double bond of 64d and its analogs such as 66c is likely to contribute to the
resistance of the C=N double bond towards the common C=N reducing agents. Efforts
were thus directed to interrupt such conjugation by converting the aldehyde 84 to its
acetals. The aldehyde 84 was first converted to the dimethyl acetal 90 in 28% yield with
84 being recovered in 26% by treatment with 2.2eq. dimethoxypropane in the presence of
a catalytic amount of p-toluenesulfonic acid monohydrate at room temperature for 19h
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(Figure 31).21-210 Similar results were obtained when 84 was treated with methanol in the
presence of a catalytic amount of bismuth nitrate at room temperature for 21h.211 The low
yield of the acetal 90 was probably due to its great tendency to go back to the starting 2-
pyrazoline 64d to reestablish the favored conjugation of the carbonyl group and the C=N
0 0
OEt a Et
Cbz-lN CHO Q Cbz-N OMe
28% yield N OMe
84 90
48% yield b
Conditions:
0
a: 1.5eq. dimethoxypropane, p-toluenesulfonic acid monohydrate,
OEt MeH, .. , overnight
Cbz-N / 0N/ b; 2eq. 1,2-ethanediol, refluxing benzene, p-toluenesulfonic
o acid monohydrate, 7h
91
Figure 31. Protection of the aldehyde 84
double bond under the reaction conditions. Increasing the yield of the acetal 90 was not
pursued further since it was felt that the acetal 90 would not survive the mild acetic
condition such as acetic acid used as the reaction solvent for reduction with NaBCNH 3 .
Efforts were then directed to convert 64d to the cyclic acetal 91 by treatment with 1, 2-
ethanediol which is likely to be more stable under the mild acidic condition than the
dimethyl acetal 90. Thus, the cyclic acetal 91 was obtained in 48% yield when 64d was
treated with 2eq. 1, 2-ethanediol in refluxing benzene for 7h in the presence of a catalytic
amount of p-toluenesulfonic acid monohydrate with the water being removed from the
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reaction mixture by using a Dean-Stark trap.2 12 The cyclic acetal 91 was treated with Seq.
sodium cyanoborohydride 17 3'175,176 in acetic acid at room temperature overnight in the
hope of reducing the isolated C=N bond of 91. Unfortunately, no reduction occurred and
most of the starting cyclic acetal 91 was recovered based on the crude 'H NMR, mass
spectrum and TLC analysis.
Efforts were subsequently directed to selectively reduce the ester group
conjugated to the C=N double bond of 64d to the hydroxyl group so that the
corresponding conjugation will be interrupted. The use of NaBH 4 as the reducing agent to
achieve such reduction was investigated since 64d was reduced to the alcohol 80 (Figure
28) with sodium borohydride in EtOH at room temperature for 23h based on the crude 'H
NMR and mass spectrum although the crude yield was less than 50%. It was noticed that
NaBH 4 was used to reduce the ester group (isolated or conjugated to C=N bond) to the
hydroxyl group in the mixture of CH30H and THF (1:1 ratio) in good to excellent
yield. 157 , 166, 213 Thus the reaction of 64d with NaBH 4 in the mixture of CH 3OH and THE
(1:1 ratio) under different conditions was studied. The results are summarized in Figure
32 and Table 7.
When 64d was treated with 1.1 eq. NaBH 4 at room temperature for 7h, three
products 80, 81 and 92 were obtained (Table 7, Entry 1), indicating that the
transesterification competed with the reduction of the ester groups conjugated to the C=N
bond. Increasing the equivalents of NaBH 4 suppressed the transesterification but resulted
in the reduction of both ester groups of 64d. The use of 3.8eq. NaBH 4 (Table 7, Entry 2)
furnished two products 80 and 93 in 39% and 27%, respectively. Further increase of the
equivalents of NaBH 4 reduced the yield of 80 and increased the yield of 93 as evidenced
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by the result that the use of 8eq. NaBH 4 (Table 7, Entry 3) provided the two products 80
and 93 in 30% and 35% yield respectively and the use of 22eq. NaBH 4 (Table 7, Entry 4)
provided mainly 93 based on TLC and the crude 'H NMR. Thus the reaction outcome is
mainly affected by the amount of NaBH 4 used in the reduction. Either 80 or 93 can be the
major product depending on the amount of NaBH 4 used in the reduction. The use of
fewer equivalents of NaBH 4 favors the formation of 80. The opposite is true for 93.
CO 2Et CO2 Et
Cbz-N CH 2OH Cbz-N CO 2Me
CO 2Et NaBH 4  80 81
Cbz-N. CO 2Et 1:1 MeOH/THF MOH
64d Cbz-NN CH2H Cbz-N CH2H
92 93
CO2Et
Cbz-N, TBDMSCI (3.5eq.) CO2 Et
N CH 2OH Cbz-NFImidazole (3.5eq.) N CH 2OTBDMS
80 CH 2Cl 2, overnight 94
Figure 32. Reduction of 2-pyrazoline 64d with NaBH 4 and
protection of the alcohol 80 as a silyl ether
Table 7. Reduction of 64d with NaBH 4 in MeOH / THE
Entry No.# of Temperature Reaction time Results
NaBH 4  (h)
1 1.1 R.T. 7 80, 31% yield; 81, 32% yield;
92, 4% yield.
2 3.8 0 0C 5 80, 39% yield;
93, 27% yield.
3 8 0 C 5 80, 30% yield;
93, 35% yield.
4 22 R.T. 21h The product mostly is 93 based
on crude H-NMR & TLC
analysis.
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Similar to 64d, the aldehyde 84 (Figure 29) was converted to 80 and 93 in about
1:1 ratio based on the crude 'H NMR spectrum when it was treated with 2.5eq. NaBH 4 in
ethanol at room temperature for 18h, indicating that the aldehyde group conjugated to the
C=N bond can not be easily distinguished from the ester group by NaBH 4 .
Since the C=N bond of 80 and 93 is isolated, the reduction of 80 and 93 was then
investigated. Compound 93 did not change when it was treated with Seq. sodium
borohydride in methanol at room temperature for 5h and was converted to the intractable
materials when the reaction mixture was refluxed for 3h based on TLC analysis and the
crude IH NMR. The reaction of 80 with superhydride was then conducted. 5 7 To prevent
the likely participation of the OH group in the reduction process, 80 was converted to the
silyl ether 94 (Figure 32) in 90% yield by treatment with tributyldimethylsilyl chloride in
the presence of imidazole in methylene chloride.214-216 The silyl ether 94 was
subsequently treated with 1.1 eq. superhydride in methylene chloride at -78 C for .5h.
However, in contrast to the reaction of 82 with superhydride to afford the pyrazolidine 83
(Figure 29),157 no reduction occurred and some of 94 was converted into 80 via the
removal of the silyl group along with some recovered starting silyl ether 94 based on
TLC analysis, the crude 'H NMR and mass spectrum.
To determine if the isolated C=N double bond can be reduced with superhydride,
my attention was turned to the model compound 95 which contains only one ester goup.
Thus cycloaddition of ethyl acrylate with diazomethane in ethyl ether at room
temperature overnight followed by treatment of the crude cycloadduct with CbzCl
furnished 95 in 93% yield in two steps (Figure 33), which was converted to the alcohol
96 in 76% yield by treatment with 3eq. NaBH 4 in the mixture of methanol and THF (1:1
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ratio) at room temperature for 5h. The alcohol 96 was then converted into the silyl ether
97 in 72% yield by treatment with tributyldimethylsilyl chloride in the presence of
imidazole in methylene chloride overnight. Treatment of the silyl ether 97 with 2.5eq.
superhydride in methylene chloride from -78 C to room temperature for 22h followed by
exposure of the crude reduction product to CbzCl achieved the reduction of the isolated
C=N bond of 97 to afford the pyrazolidine 98 in 74% yield in two steps. I noted that the
same reduction reaction followed by treatment of the crude reduction product with 2eq.
(Boc)20 in the presence of NEt3 and 4-dimethylaminopyridine in CH 2Cl 2 did not afford
the expected BOC-protected pyrazolidine compound, most likely due to the steric
hindrance exerted by the neighboring bulky silyl group since this condition successfully
resulted in the formation of the BOC derivative of the 2-pyrazoline 64b.
=,COOEt a Cbz-N, bCH2N2 + -- COt-a_ CzN COOEt93% yield 76% yield
95
Cbz-N
Cbz-N, c Cbz-N d z-N CH2OTBDMS
N CH2OH _N CH2OTBDMS bz
96 72% yield 97 74% yield 98
Reagents: (a) i. Et2O, R.T., overnight; ii. CbzCl. (b) NaBH4 , MeOH/THF. (c) TBDMSCI (3.5eq.)
Imidazole (3.5eq.), CH2Cl2, overnight. (d) i. LiBEt3H, -78 C - R.T., CH2C 2 ; ii. CbzCl
Figure 33. Conversion of 2-pyrazoline 95 to the pyrazolidine compound 98
The failure to reduce the silyl ether 94 with superhydride, structurally similar to
the silyl ether 97, is not fully understood and further experiments need to be conducted to
determine if 94 can be reduced with superhydride. This was not done since the 2-
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pyrazoline 80 was successfully reduced to the corresponding pyrazolidine compound
with NaBCNH 3/HOAc reducing system (Figure 34). when 2-pyrazoline 80 was treated
with 6eq. NaBCNH3163,173, 175, 176 in acetic acid at room temperature for 6h followed by
treatment of the crude reduction product with CbzCl, three Cbz protected pyrazolidine
products 99, 100 and 101 were obtained in 10%, 39% and 11% yield in two steps,
respectively. The relative configuration of the 3, 4-substituents of 99 and 100 is assigned
as trans and that of 101 as cis on the basis of their NOESY spectrum. Thus 2-pyrazoline
80 was successfully reduced to the corresponding pyrazolidine compound in good yield
(~61% for two steps) in 82% diastereoselectivity. It was noted that nothing was obtained
when the reduction mixture was quenched with 1M NaOH solution175 instead of saturated
potassium carbonate solution.163
Encouraged by the successful reduction of the C=N bond of 80, the model
compound 95 (Figure 33) was attempted to be treated with NaBCNH3 in acetic acid to
reduce its C=N bond. Unfortunately, no reduction occurred and most of the starting 95
stayed intact based on the TLC analysis, the crude 'H NMR and mass spectrum after the
model compound 95 was treated with 26eq. NaBCNH3 in acetic acid at room temperature
for 29h or 26eq. NaBCNH 3 in acetic acid at reflux for 17. When the mixture of 65c and
65d was treated with 26eq. NaBCNH 3 in acetic acid at room temperature for 48h, no
change of the starting mixture was observed based on TLC analysis. When additional
10eq. NaBCNH 3 was added to this reaction mixture and the resulting mixture was
refluxed for 6h, no reduction occurred and most likely the Cbz groups of 65c and 65d
(Figure 24) were replaced by the acetyl group based on the crude 'H NMR and mass
spectra. Based on the above observations, it was indicated that the C=N double bonds of
65
0
CO 2Et CO 2Et
CO2Et Cbz-N Cbz-N CH2  Cbz-N. OE N CH20Cbz NN
Cbz-NN CH2OH Cbz Cbz Cbz
80 99 100 101
10% yield 39% yield 11% yield
-- C0 2Et ,-CO2Et
il Cbz-NN CO 2 Et -. N CO2Et
OOEt 0 OEt
69f 102
41% yield
Conditions: i. 6eq. NaBCNH 3, AcOH; ii. 2eq. CbzCl, 2eq.NaHCO 3, 1:1 CH 2C12/ H2O
Figure 34. Reduction of 2-pyrazolines with NaBCNH 3/HOAc
64d and its related compounds are resistant to the common C=N double bond reducing
agents due to its conjugation with the carbonyl group or phenyl group.
As expected, the protected 2-pyrazoline 69f was reduced to the corresponding
pyrazolidine compound 102 (Figure 34) in 41% yield in two steps after it was treated
with 6eq. NaBCNH 3 in acetic acid for 5h followed by the treatment of the crude
cycloadduct mixture with 1.1 eq. CbzCl in the presence of NaHCO 3 in the mixture of
CH 2Cl2 /H20 (1:1). I noted that the treatment of the crude cycloadduct mixture with 2eq.
(Boc)20 in the presence of NEt3 and 4-dimethylaminopyridine in CH 2C12 for 18h15 7
failed to afford the expected protected pyrazolidine compound and resulted in the
formation of intractable materials. One of the synthetic targets, compound 60 (Figure 18),
will be obtained upon deprotection of the pyrazolidine compound 102. Obviously,
compound 100 can also be converted to the target compound 60 (Figure 18) after
functional group transformations.
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Figure 35. Possible routes to access the target compounds 58 and 59
2.2.3 Possible routes to access the target compounds 58 and 59
The strategy used for the conversion of the 2-pyrazoline 64d to the pyrazolidine
100 can be applied in the synthesis of the target compounds 58 and 59. Shown in Figure
35, selective reduction of the ester group conjugated to the C=N bond of the 2-pyrazoline
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66c will lead to formation of the alcohol 103, which can be converted to the pyrazolidine
compound 104 after protection of the hydroxyl group of 103 followed by reduction of the
C=N bond with NaBCNH3 /HOAc reducing system. The target compound 58 will be
obtained after functional group transformations of the pyrazolidine compound 104.
Similar route can be used for the synthesis of the target compound 59 (Figure 35).
2.3 1,3-dipolar cycloadditions of trimethylsilyldiazomethane revisited
Trimethylsilyldiazomethane has been most frequently used as a source of carbene
in the synthesis of Me3Si-substituted cyclopropanes2 17 and has enjoyed only limited
synthetic utility in 1, 3-dipolar cycloadditions. In fact, Seyferth reported that among a
series of dipolarophiles examined, only acrylonitrile reacted with TMS diazomethane to
produce a cycloadduct in a synthetically useful yield.218 ,2 19 Recently, with the
commercial availability of TMS diazomethane, it has become somewhat more popular as
a synthetic reagent, particularly in the preparation of novel amino acid analogs.1 63,220
As stated in Section 1.7 and shown in Figure 22, 1, 3-dipolar cycloadditions of
diazoalkanes and cp-unsaturated esters yield 1-pyrazolines, with the regioselectivity
being such that the terminal nitrogen of the diazoalkane attacks the c-carbon of the ester,
which tend to be unstable and isomerize to typically yield the conjugated 2-pyrazoline.
A survey of the recent literature indicates that the regioselectivity of the double
bond isomerization of TMS substituted 1-pyrazolines is variable and at first glance,
unpredictable. Carreira and Kanemasa have reported the dipolar cycloaddition of
TMSCHN 2 with camphorsultam and oxazolidinone derivatives, respectively.1
63
,
220
,
22 1
These 1-pyrazoline products undergo proteodesilylation to yield 2-pyrazolines (107a and
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107b) or loss of the proton cc to TMS (108) (Figure 36). On the other hand, Barluenga et
al.157 recently described the cycloaddition of the menthol ester of trans-cinnamic acid to
produce the conjugated 2-pyrazoline 109, with retention of the TMS group. Moreover, it
was found that the cycloaddition of trimethylsilyldiazomethane to diethyl glutaconate
yielded different products under different conditions (See Section 2.1 and ef.222)
R
NX
N TMS R
NN
o N ' S
~N H 0 02
H 0 1
107a 107b
TMS Ph
HN ,
109
Figure 36. Some 2-pyrazolines from the 1,3-dipolar cycloaddition of
TMSCHN 2 and a, P-unsaturated esters
In an effort to develop a mechanistic rational for the isomerization which could
account for the products obtained, a systematic survey of dipolar cycloadditions between
TMS diazomethane and a, n-unsaturated dipolarophiles was undertaken by me and
another doctoral student, Dragan Simovic. The dipolarophiles vary in terms of the size of
the electron withdrawing group (EWG) and the substituents at the p-carbon. The results
derived from my work are summarized in Table 8. Because 1 and 2-pyrazolines oxidize
readily to pyrazoles, the cycloaddition products were immediately converted to the Cbz
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derivatives of the 2-pyrazolines. As shown in Table 8, three products may be obtained
from the isomerization of the intermediate 1-pyrazoline; the conjugated 2-pyrazoline (a),
the desilylation product (c), and in some instances, we also observed a third type of 2-
pyrazoline (b) that results from a loss of the proton cc to the TMS group.
In contrast to earlier reports, it was found that the acrylates react with
trimethylsilyldiazomethane at ambient temperature to provide cycloadducts in good to
excellent yield (Entries 1-4). Products b and c were formed exclusively with little
selectivity.
Methyl acrylate, derived from the treatment of acryloyl choride with methanol in
toluene in the presence of pyridine, was reacted with trimethylsilyldiazomethane in a
mixture of toluene and hexane at room temperature for 8.5h followed by exposure of the
crude cycloadduct mixture to CbzCl to afford the two protected products 11b and 110c
in 12% and 8% yield starting from acryloyl choride respectively (Table 8, Entry 1). In
this reaction, the crude methyl acrylate was not purified due to the formation of the
azeotrope of methanol and methyl acrylate and directly subjected to cycloaddition. Some
of it was probably lost during workup, possibly responsible for the low overall yield.
The results from the reactions of t-butyl acrylate with
trimethylsilyldiazomethane are not consistent. When it was reacted with 3eq.
trimethylsilyldiazomethane in the mixture of toluene and hexane at room temperature for
22h followed by the treatment of the crude cycloadduct mixture with CbzCl, two
products 111a and 111e were obtained in the yield of 1.5% and 72.5% in two steps,
respectively (Table 8, Entry 3) after careful purification of the crude reaction product.
Product 111a was not stable and oxidized on standing as indicated by the high resolution
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mass spectrum. When the same reaction was done the second time, two products 111b
and 111e were obtained in the yield of 3% and 73% in two steps, respectively (Table 8,
Entry 4). 111b and 111c were afforded in 31% and 40% yield, respectively (Table 8,
Table 8. Dipolar cycloadditions of TMS diazomethane and various dipolarophiles
TMS R RTMS, R /
R OR TMSCH Cbz'N CR'N CO2 R' N b ' 2 R'
Cbz z
a b c
Entry Cmpd. R R' Conditions %Yielda Product Ratio
a:b:c
1 110 H OMe 2eq. TMSCHN 2 , PhCH3/ 20 0:60:40
hexane (1:1), RT, 8.5 hr
2 111 H O-tBu 3eq.TMSCHN 2, PhCH3/ 71 0:44:56
hexane (1:1), RT, 22 hr
3 111 H O-tBu 3eq. TMSCHN 2, PhCH3/ 74 2:0:98
hexane (1:1), RT, 22 hr
4 111 H O-tBu 3eq. TMSCHN 2, PhCH3/ 76 0:4:96
hexane (1:1), RT, 22hr
5 112 Me OEt 3eq.TMSCHN 2 , 49 16:16:68
Toluene, reflux, 8.5 hr
6 112 Me OEt 3eq. TMSCHN 2 , PhCH3/ 41 78:0:22
hexane (1:1), reflux,
8.5 hr
7 113 Ph OEt 2eq. TMSCHN 2, PhCH3/ 31 15:0:85
hexane (1:1), reflux,
8.5 hr
'Isolated yield. Yield based on acryloyl chloride.
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Entry 2) when the same reaction was done the third time. The above discrepancy is not
understood. Probably the cycloaddition reaction and/or the isomerization of the 1-
pyrazoline are so sensitive to the reaction conditions and/or the reaction workup
conditions that subtle change of these conditions results in different product distributions.
The cycloaddition of t-butyl acrylate with trimethylsilyldiazomethane followed by
exposure of the crude cycloadduct mixture to acid (CF 3COOH/CH 2Cl 2)163 afforded the
expected 2-pyrazoline 111d (Figure 37) in 47% yield via the proteodesilylation. The
N CO 2t-Bu NN N, N CO 2Et
H N CO 2Et N CO 2Et N CO 2Et
H H H Cbz
111d 112d 112e 112f 112g
TMS TMS Ph TMS Ph
N 
NCbz- 
N CO 2Et 'N CO 2Et 'N CO 2Et 'N CO 2Et
Cbz Cbz H
112h 112i 113d 113e
Figure 37. Some other products from the dipolar cycloaddition of TMSCHN 2
and a,p- unsaturated esters
same process followed by treatment of the crude cycloadducts with CbzCl furnished the
protected 2-pyrazoline 111 c in 38% overall yield.
The p-substituted dipolarophiles (Entries 5-7) require elevated temperatures or
extended reaction times to provide cycloadducts in moderate yields. Ethyl crotonate was
not sufficiently reactive in the cycloaddition with trimethylsilyldiazomethane at room
temperature. When Ethyl crotonate was reacted with 3eq. trimethylsilyldiazomethane in
the mixture of toluene and hexane (1:1 ratio) at room temperature for 23h followed by the
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acidic workup (CF 3COOH / CH 2 Cl 2),163 the formation of the two compounds 112d and
112f (Figure 37) was indicated before acidic workup and the formation of the two
pyrazoles 112d and 112e (Figure 37) after acidic workup by the crude mass spectrum.
However, the crude yield was very low (less than 15%) before acidic workup and after
acidic workup. Although the formation of the two compounds 112d and 112f (Figure 37)
was indicated when the same cycloaddition was done in the presence of 2.1 eq.
BF 3.OEt 2 167 without acidic workup, low crude yield (30%) was obtained. A complicated
mixture was obtained in low crude yield (45%) when the same reaction was conducted
for 19 days without acidic work up. When ethyl crotonate was reacted with 3eq.
trimethylsilyldiazomethane in the mixture of toluene and hexane at reflux for 22h
followed by acidic workup (CF 3COOH/CH2 C12),163 the two pyrazoles 112d and 112e
(Figure 37) were obtained in 6% and 33%, respectively. When the reaction was carried
out at reflux for 8.5h followed by treatment with CbzCl, the conjugated 2-pyrazoline
112a and the pyrazole 112g (Figure 37), derived from the oxidation of the desilylated 2-
pyrazoline 112f (Figure 37), were obtained in 32% and 9% yield, respectively (Table 8,
Entry 6). The relative configuration of the 4, 5 substituents of 112a is assigned as trans
on the basis of its NOESY spectrum. At the same time, two pyrazole compounds
containing TMS group were also obtained in 5% and 4% yield, respectively. They turned
out to be the regioisomers 112h and 112i (Figure 37) in terms of the position of the Cbz
group, which is supported by the observation that they were converted to the same
unprotected 2-pyrazole 112d (Figure 37) upon the removal of the Cbz group by treatment
with H2 (1 atm) in the presence of palladium on activated carbon. The specific
regioisomers were not determined. However, when ethyl crotonate was reacted with 3eq.
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trimethylsilyldiazomethane in toluene at reflux for 8.5h followed by treatment with
CbzCl, the conjugated 2-pyrazoline 112a and the 2-pyrazoline 112b and the desilylated
2
-pyrazoline 112c were obtained in the ratio of 16:16:68 in 49% overall yield (Table 8,
Entry 5).
Reaction of ethylcinnamate with 2eq. trimethylsilyldiazomethane in the mixture
of toluene and hexane at reflux for 8.5h followed by treatment with CbzCl furnished the
conjugated 2-pyrazoline 113a in 5% yield, the desilylated 2-pyrazoline 113c in 15% yield,
the pyrazole 113d (Figure 37) in 11% yield and the unprotected 113e (Figure 37) in 2%
yield (Table 8, Entry 7). Formation of 113b was not observed.
The cycloaddition of ethyl 3, 3-dimethylacrylate with trimethylsilyldiazomethane
was not achieved under different conditions. No reaction occurred when ethyl 3,3-
dimethylacrylate was treated with 3eq. trimethylsilyldiazomethane in the mixture of
toluene and hexane at room temperature for 22h based on the crude H NMR and mass
spectrum. Intractable material was obtained in low mass balance when the same reaction
was carried out for 19 days, or when ethyl 3,3-dimethylacrylate was treated with 3eq.
trimethylsilyldiazomethane in the mixture of toluene and hexane at reflux for 22h or at
room temperature for 22h in the presence of 2.1eq. BF3.OEt2 based on the crude 'H NMR
and mass spectra.
Based on the above observations, we speculate that product distributions of
dipolar cycloadditions between TMS diazomethane and c, p-unsaturated dipolarophiles
may be affected by the cycloaddition conditions, the reaction workup conditions, and/or
the nature of the dipolarophiles. Probably the cycloaddition reaction and/or the
isomerization of the 1-pyrazoline are so sensitive to the reaction conditions and/or the
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reaction workup conditions that subtle change of these conditions results in different
product distributions. The complete picture of the cycloaddition of
trimethylsilyldiazomethane is under investigation.
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3. Experimental Section
3.1 General procedure
All reactions involving air-sensitive compounds were carried out under a N 2
atmosphere. All common reagents and solvents were obtained from commercial suppliers
and used without any further purification unless otherwise indicated. Solvents were dried
by standard methods. Melting points were obtained using a MEL-TEMP capillary
apparatus and are uncorrected. Thin layer chromatography was performed using
ANALTECH 0.25mm silica gel GHLF plates. The chromatograms were visualized under
ultraviolet light and/or by staining with a Ce/Mo reagent (prepared by dissolving
phosphomolybdic acid (2g), cerium(iv) sulfate (lg), and conc. sulfuric acid (10 mL) in
H20 (90 mL)) or Iodine. Flash column chromatography was carried out on silica gel 60,
230 240 mesh. Routine NMR measurements were recorded on Bruker AVANCE-400
or AVANCE-600 spectrometers. H NMR: splitting pattern abbreviations are: s, singlet;
br s, broad singlet; d, doublet; t, triplet; q, quartet; m, multiplet. 13C NMR: multiplicities
were determined by DEPT; abbreviations are: q, CH3 ; t, CH 2 ; d, CH; s, quaternary
carbons. NOESY, COSY, HETCOR experiments were carried out on Bruker AVANCE-
400 or AVANCE-600 spectrometers. High-resolution mass spectra (HRMS) were
obtained with a VG 7070 mass spectrometer at University of California Reverside Mass
Spectrometry Facility.
3.2 Materials and methods for molecular modeling study
The crystal structures (Protein Data Bank Id: 1 YAE, 1 TT 1 and 1 GR2) were
downloaded as PDB files from the Protein Data Bank. Residue numbers referred to in
this work correspond to those of iGluR6 downloaded from The National Center for
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Biotechnology Information (accession number NP_062182 for rat iGluR6). A fixed shell
of residues within 10A of the ligand was used as the receptor. To adapt the crystal
structure to the AMBER* force field explicit hydrogen atoms were added, then deleted.
All crystallographically determined water molecules were removed to simplify the
calculations. Amino acid side chains and ligands were subjected to energy minimizations
using the AMBER* united atom force field with the programs MacroModel (v. 6.5) and
Batchmin (v. 6.5)223 running on a Silicon Graphics 02 workstation. No solvation was
employed; however, a distance dependent dielectric constant of 4r was used. Calculations
for low-mode docking searches were performed as described above. In addition ligands
were subjected to explicit translation/rotations, using the Batchmin MOLS command,
randomly varied from 0.1-0.5 A and 0-90" respectively, to ensure efficient orientational
sampling of all allowed binding modes (LMCS/MOLS). Backbone movements of the
receptor were not allowed. A global search approach was undertaken in which the
starting geometry for each Monte Carlo/Energy Minimization (MC/EM) cycle is taken
randomly from the pool of structures found thus far, and the one selected is the one that
has been used the least number of times previously as a starting structure. A minimum of
one thousand, but not more than five thousand, MC/EM cycles were performed for each
ligand-receptor pair. Gradient convergence to 0.05 kJ/Ang-mol RMS and an energy
window for saved structures of 25 kJ/mol was employed.
3.3 Synthesis
General Procedure for Cycloaddition Reactions: Reactions were performed under the
conditions described in Table 1 and Table 8. Solvent was evaporated under reduced
pressure and the residue was purified by either gravity or flash colunm chromatography
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(silica gel) using ethyl acetate and hexane as the eluant. General Procedure for
Preparation of Cbz derivatives: CbzCl (1.1 mmol) and a solution of NaHCO 3 (1.5mmol)
in H20 (5m1) were sequentially added to a solution of the corresponding 2-pyrazoline
(immol) in CH 2C12 (5ml) at room temperature. The resulting mixture was stirred at room
temperature overnight. The organic layer was extracted with CH 2Cl 2 (3 x 15mL), dried
over Na2SO 4 , and filtered. Solvents were evaporated under reduced pressure and the
residue was purified by flash chromatography over silica gel with hexane/ethyl acetate as
eluents. Protected 2-pyrazolines were obtained in good yields, and they proved to be air-
stable.
4-Ethoxycarbonylmethyl-4, 5-dihydro-1H-pyrazole-3,5-dicarboxylic acid ethyl ester
[64b]
Yellow oil; 90% yield. 'H NMR (CDCl 3, 400MHz) 6 6.74 (bs, 1H), 4.26 (q, 2H, J= 7.1
Hz), 4.11 (q, 2H, J=7.2Hz), 3.81 (t, 1H, J= 10.2Hz) 3.64-3.56 (i, 1H), 3.45 (dd, 1H,
J=6.9, 10.1Hz), 2.86 (dd, 1H, J=3.5, 16.4Hz), 2.46 (dd, 1H, J=10.4, 16.4Hz), 1.31 (t, 3H,
J=7.1Hz), 1.22 (t, 3H, J=7.1Hz). "C NMR (CDCl 3, 100.6MHz) 6 172.10 (s), 162.76 (s),
144.07(s), 61.40, 61.11, 55.09, 40.34, 35.35, 14.62, 14.52. LC MS (MH+) 229.
4-Ethoxycarbonylmethyl-4, 5-dihydro-pyrazole-1, 3-dicarboxylic acid 1-benzyl ester
3-ethyl ester [64d]
Light yellow solid; m.p. 91-94 C; 93% yield. H NMR (CDCl 3, 400MHz) 6 7.45-7.28 (in,
5H), 5.29 (d, 1H, J=12.3Hz), 5.25 (d, 1H, J=12.3Hz), 4.32 (q, 2H, J=7.1Hz), 4.21 (s, 1H),
4.13 (q, 2H, J=7.1Hz), 3.75-3.82 (in, 2H), 2.83 (dd, 1H, J=2.9, 16.7Hz), 2.53 (dd, 1H,
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J=9.9, 16.8Hz), 1.33 (t, 3H, J=7.1Hz), 1.23 (t, 3H, J=7.1Hz). 3 C NMR (CDCl3,
100.6MHz) 6 171.23 (s), 161.87 (s), 152.78 (s), 149.00 (s), 135.98 (s), 128.95, 128.94,
128.84, 68.68, 62.31, 61.47, 53.37, 41.36, 36.40, 14.58, 14.53. HRMS (DCI) calculated
for C1sH 23N206 (MH+) 363.1556; found 363.1567.
trans-4-Ethoxycarbonylmethyl-5-phenyl-3,4-dihydro-2H-pyrazole 
-3-carboxylic acid
ethyl ester [65a, major isomer]
Yellow oil; 73% yield. H NMR (CDCl 3, 400MHz) 6 7.35-7.26 (m, 5H), 4.77 (d, 1H,
J=6.4Hz), 4.32-4.23 (m, 211), 4.20-4.07 (m, 2H), 3.54 (ddd, 1H1, J=3.7, 6.3, 9.9Hz), 2.85
(dd, 1H, J=3.7, 16.2Hz), 2.67 (dd, 1H, J=9.8, 16.2Hz). 1.34 (m, 3H), 1.21 (in, 3H). 13C
NMR (CDCl3, 100.6MHz) mixture of isomers, 6 171.80, 162.73, 141.41, 141.12, 129.30,
128.89, 128.57, 128.55, 126.42, 70.95, 61.48, 61.20, 49.90, 35.37, 14.64, 14.52. LC MS
(MH+) 305.
trans -4-Ethoxycarbonylmethyl-3-phenyl-4, 5-dihydro-pyrazole-1, 5-dicarboxylic
acid 1-benzyl ester 5-ethyl ester [65c]
Colorless oil; 68% yield. 1H NMR (CDCl3 , 400MHz) 6 7.40-7.20 (m, 10H), 5.25 (d, 2H,
J=4.1Hz), 5.16 (d, 1H, J=4.0Hz), 4.36 (q, 2H, J=7.1Hz), 4.18 (q, 2H, J=7.1 Hz), 3.65 (ddd,
1H, J=3.7, 4.0, 10.0Hz), 2.95 (dd, 1H, J=3.4, 16.6Hz), 2.67 (dd, 1H, J=10.2, 16.6Hz),
1.38 (t, 3H, J=7.1Hz), 1.25 (t, 3H, J=7.1Hz). 13C NMR (CDCl 3, 100.6MHz) 6 170.95 (s),
161.79 (s), 152.52 (s), 147.71 (s), 140.28 (s), 135.77 (s), 129.43, 128.81, 128.67, 128.59,
125.78, 69.15, 68.68, 62.48, 61.58, 51.70, 36.24, 14.60, 14.55. HRMS (DCI) calculated
for C2 4H27N2 O 6 (MH) 439.1869; found 439.1855.
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cis -4 -Ethoxycarbonylmethyl-5-phenyl-4, 5-dihydro-pyrazole-1, 3-dicarboxylic acid
1-benzyl ester 3-ethyl ester [65d]
Yellow oil; 55% yield. IH NMR (CDCl3, 400MHz) 6 7.32-7.27 (m, 7H), 7.07-7.05 (in,
3H), 5.65 (d, 1H, J=12.2Hz), 5.21 (d, lH, J=12.3), 5.11 (d,1H, J=12.3Hz), 4.36 (q, 2H,
J=7.1 Hz), 4.27 (ddd, 1H, J=3.5, 11.1, 12Hz), 3.93 (q, 2H, J=7.1Hz), 3.03 (dd, 1H, J=3.5,
17.5Hz), 2.09 (dd, 1H, J=11.0, 17.5Hz), 1.39 (t, 3H, J=7.1Hz), 1.11 (t, 3H, J=7.1Hz). 13C
NMR (CDCl3, 100.6MHz) 6 171.66, 162.12, 152.36, 147.53, 135.90, 135.81, 129.10,
128.80, 128.76, 128.55, 128.45, 68.51, 66.63, 62.41, 61.14, 46.52, 32.19, 14.60, 14.39.
HRMS (DCI) calculated for C2 4 H27N20 6 (MH+) 439.1869; found 439.1865.
trans-4-Ethoxycarbonylmethyl-4, 5-dihydro-1 H-pyrazole-3, 5-dicarboxylic acid
diethyl ester [66a]
Yellow oil; yield: 49% (refluxing benzene) or 67% (refluxing toluene). 'H NMR (CDC13
400MHz) 6 6.58 (bs, 1H), 4.28 (d, 1H, J=4.5Hz), 4.22 (q, 2H, J=7.1Hz), 4.15 (q, 2H,
J=7.1Hz), 4.09 (q, 2H, J=7.1 Hz), 3.84 (ddd, 1H, J=3.9, 4.4, 10.0Hz), 2.77 (dd, 1H, J=3.8,
15.8Hz), 2.51 (dd, 1H, J=10.0, 15.8Hz), 1.27 (t, 3H, J=7.1Hz), 1.22 (t, 311, J=7.1Hz),
1.19 (t, 3H, J=7.1Hz). 13C NMR (CDCl 3,100.6MHz) 5 171.24(s), 171.21(s), 161.99(s)
143.41(s), 66.97, 62.42, 61.62, 61.25, 44.81, 35.01, 14.53, 14.46, 14.40. HRMS (DCI)
calculated for C13H2 1N2 0 6 (MH+) 301.1400, found 303.1404.
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trans -4 -Ethoxycarbonylmethyl-4, 5-dihydro-pyrazole-1, 3, 5-tricarboxylic acid 1-
benzyl ester 3, 5-diethyl ester [66c]
Yellow oil; 87% yield. 1H NMR (CDCl 3, 400MHz) 6 7.42-7.32 (m, 5H), 5.37-5.28 (m,
2H), 4.72 (d, 1H, J=5.5Hz), 4.35 (q, 2H, J=7.1Hz), 4.16 (q, 4H, J=7.1 Hz), 3.84-3.79 (m,
lH), 2.94 (dd, 1H, J=3.7, 16.3Hz), 2.71 (dd, 1H1, J=8.8, 16.3Hz), 1.37 (t, 3H, J=7.1Hz),
1.25 (t, 6H, J=7.1Hz). 3C NMR (CDCl 3, 100.6MHz) 6 170.24 (s), 169.13(s) 161.38
(s), 152.37(s), 147.22 (s), 135.68 (s), 128.94, 69.08, 66.02, 62.61, 61.71, 47.30, 36.09,
14.56, 14.49, 14.38. HRMS (DCI) calculated for C21H27N20s (MH+) 435.1767; found
435.1758.
Ethyl 3-(4-ethyl carboxymethylene-5-phenyl) pyrazole carboxylate [67J
Yellow oil; 11 NMR (CDCl 3,400MHz) 6 9.37 (bs, 1H), 7.51-7.38 (m, 5H), 4.32 (q, 2H,
J=7.1Hz), 4.17 (q, 2H, J=7.1Hz), 3.86 (s, 2H), 1.32 (t, 3H, J=7.1Hz), 1.24 (t, 3H,
J=7.1Hz). 13C NMR (CDC13, 100.6MHz) 6 171.64, 161.44, 130.08, 129.32, 128.56, 61.55,
61.39, 30.44, 14.57, 14.49. HRMS (DCI) calculated for C16H19N204 (MH) 303.1345,
found 303.1351.
3, 4-cis-4, 5-trans-3-Ethoxycarbonylmethyl-1, 5-diaza-bicyclo[3.1.O]hexane-2, 4, 6-
tricarboxylic acid triethyl ester [68]
Yellow oil; 15% yield (refluxing benzene) or 22% (refluxing toluene). 111 NMR (CDC13,
400MHz) 8 4.49 (d, 1H, J=18.2Hz), 4.41 (d, 1H, J=8.8Hz), 4.36-4.07 (m, 10H), 3.17 (dd,
1H, J=3.6, 16.4Hz), 2.71 (dd, 1H, J=10.2, 16.4Hz), 1.34 (t, 3H, J=7.1Hz), 1.31 (t, 311,
J=7.1Hz), 1.27 (t, 3H, J=7.1Hz), 1.25 (t, 3H, J=7.1Hz). 13C NMR (CDCl 3 100.6MHz) 6
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171.54 (s), 169.72 (s), 169.68 (s), 162.15 (s), 140.20 (s), 71.13, 62.30, 61.65, 61.63,
61.25, 52.71, 46.38, 36.59, 14.74, 14.57, 14.53, 14.51. HRMS (DCI) calculated for
C1 H2 6N2 08 (MH+) 387.1767; found 387.1758.
Ethyl 3-(4-ethyl carboxymethylene-5-trimethylsilyl) pyrazole carboxylate [69a] and
Ethyl 4-(3-ethyl carboxymethylene-5-trimethylsilyl) pyrazole carboxylate [69b]
Yellow oil; 58 % overall yield. Major isomer; H NMR (CDCl 3, 400MHz) 6 7.32
(bs,1H), 4.36 (q, 2H, J=7.1Hz), 4.17 (q, 2H, J=7.1Hz), 3.90 (s, 2H),1.36 (t, 3H, J=7.1Hz),
1.26 (t, 3H, J=7.1Hz), 0.40 (s, 9H). 13C NMR (CDCl3, 100.6MHz) 6 171.19, 161.97,
145.15, 140.65, 124.21, 61.58, 61.39, 31.04, 14.61, 14.57, 1.43. HRMS (DCI) calculated
for C13H23N2 O4 Si (MH+) 299.1427, found 299.1416. Minor isomer; 1H NMR (CDCl3
400MHz) 6 9.08 (bs, 1H), 4.38 (q, J=7.2Hz, 2H), 4.18 (q, J=7.1Hz, 2H), 3.84 (s, 2H),
1.38 (t, J=7.1Hz, 3H), 1.27 (t, J=7.2Hz, 3H), 0.36(s, 9H). 13C NMR (CDC 3, 100.6MHz) 6
171.53, 161.83, 144.24, 141.61, 124.95, 61.50, 61.35, 30.58, 14.61, -0.94. HRMS (DCI)
calculated for C 13H23N20 4Si (MH+) 299.1427, found 299.1437.
4-Ethoxycarbonylmethyl-3-trimethylsilanyl-4,5-dihydro-pyrazole-1,5-dicarboxylic
acid 1-benzyl ester 5-ethyl ester [69c]
Yellow oil; IH NMR (CDCl3, 400MHz) 6 7.39-7.21 (m, 5H), 5.25-5.10 (m, 2H), 4.37 (d,
1H, J=4.8Hz), 4.09 (q, 2H, J=7.2Hz), 4.08 (q, 2H, J=7.2Hz), 3.53-3.49 (m, 1H), 2.60 (dd,
1H, J=3.6, 15.9Hz), 2.32 (dd, 1H, J=9.6, 15.9Hz), 1.18 (t, 6H, J= 7.0Hz), 0.20 (s, 9H);
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13C NMR (CDCl 3, 100.6MHz) 6 171.63(s), 171.52 (s), 164.53(s), 153.81(s), 129.99,
129.74, 69.30, 64.59, 63.20, 62.82, 54.81, 37.94, 15.63, 15.56, 0.00. HRMS (DCI / NH3)
caled for C21H 31N 206 Si (MH) 435.1951; found 435.1951.
4-Ethoxycarbonylmethyl-4,5-dihydro-pyrazole-1,5-dicarboxylic acid 1-beuzyl ester
5-ethyl ester [69d]
Yellow oil; 'H NMR (CDCl 3, 400MHz) 6 7.36-7.27 (m, 5H), 6.87 (s, 1H), 5.30-5.19 (m,
2H), 4.42 (d, 1H, J=5.6Hz), 4.16 (q, 4H, J=7.2Hz), 3.60-3.55 (m, 1H), 2.60 (d, 2H,
J=7.6Hz), 1.24 (t, 6H, J= 7.2Hz); 13C NMR (CDC13 100.6MHz) 6 170.23(s), 169.67(s),
152.76(s), 147.04, 135.98(s), 128.81,128.64, 68.38, 63.12, 62.27, 61.60, 48.72, 36.61,
14.42, 14.28. HRMS (DCI / NH 3) calcd for CI 8H23N20 6 (MH+) 363.1556; found
363.1562.
4-Ethoxycarbonylmethyl-5-trimethylsilanyl-4,5-dihydro-pyrazole-1,3-dicarboxylic
acid diethyl ester 169e]
Yellow oil; 'H NMR (CDCl3, 400MHz) 6 4.22 (q, 2H, J=6.9Hz), 4.20 (q, 2H, J=6.9Hz),
4.02 (q, 2H, J=7.2Hz), 3.69 (d, 1H, J=5.6Hz), 3.55-3.50 (m, 1H), 2.64 (dd, 1H, J=3.4,
16.2Hz), 2.44 (dd, 1H, J=9.4, 16.2Hz), 1.25 (t, 3H, J= 7.0Hz), 1.24 (t, 3H, J= 7.2Hz),
1.14 (t, 3H, J= 7.0Hz), 0.00 (s, 9H); 13C NMR (CDCl 3, 100.6MHz) 6 170.63(s),
161.76(s), 152.74(s), 148.19(s), 62.92, 61.87, 60.94, 51.73, 43.64, 37.56, 14.55, 14.17, -
2.84. HRMS (DCI / NH3) caled for C1H629N 2O6Si(MH+) 373.1795; found 373.1792.
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4
-Ethoxycarbonylmethyl-4,5-dihydro-pyrazole-1,5-dicarboxylic acid diethyl ester
[69fJ Yellow oil; H NMR (CDCl, 400MHz) 6 6.80 (s, 1H), 4.36 (d, 1H, J=5.6Hz), 4.16
(q, 2H, J=7.2Hz), 4.11( q, 2H, J=7.1Hz), 3.55-3.49 (m, 1H), 2.56 (d, 2H, J=7.2Hz), 1.21
(t, 3H, J= 7.0Hz), 1.20 (t, 3H, J=7.0Hz); 13C NMR (CDCl 3, 100.6MHz) 6 169.93(s),
169.42(s), 152.67(s), 146.40, 62.75, 62.47, 61.94, 61.30, 48.38, 36.36, 14.49, 14.10,
14.06. HRMS (DCI / NH 3) caled for C13H2 1N2 O 6 (MH+) 301.1400; found 301.1401.
4-Ethoxycarbonylmethyl-pyrazole-1,3-dicarboxylic acid 1-benzyl ester 3-ethyl ester
[70]
Yellow oil; 1H NMR (CDCl 3, 400MHz) 6 8.19 (s, 1H), 7.49-7.46 (m, 2H), 7.41-7.37 (n,
3H), 5.48 (s, 2H), 4.40 (q, 2H, J=7.1Hz), 4.17 (q, 2H, J=7.1Hz), 3.80 (s, 2H), 1.38 (t, 3H,
J=7.1Hz), 1.25 (t, 3H, J=7.1Hz). 13C NMR (CDC 3, 100.6MHz) 6 170.78(s), 162.17(s),
149.08(s), 146.33(s), 134.34(s), 132.34, 129.55, 129.47, 129.16, 119.62 (s), 70.96, 61.97,
61.52, 30.44, 14.62, 14.56. LCMS (MH+) 361.
4-Ethoxycarbonylmethyl-4,5-dihydro-pyrazole-1,3-dicarboxylic acid diethyl ester
[71]
Aqueous saturated K2 CO 3 solution (3ml) and ClCOOEt (0.16mL, 1.69mmol) were
sequentially added to a solution of the pyrazoline 64b (193mg, 0.85mmol) in CH 3CN
(3mL) at room temperature. The resulting mixture was stirred overnight. The organic
layer was extracted with ethyl acetate, dried over Na2SO 4 and filtered. Solvents were
evaporated and the residue was purified by column chromatography using silica gel with
hexane/ethyl acetate 80/20 and 65/35 as eluents to furnish the 2-pyrazoline 71 (188mg,
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74%) as yellow solid. 1H NMR (CDCl3 400MHz) 6 4.33 (q, 2H, J=7.OHz), 4.31 (q, 2H,
J= 7 .0Hz), 4.24-4.21 (in, 1H), 4.15 (q, 2H, J=7.lHz), 3.83-3.74 (in, 2H), 3.00 (dd, 1H1,
J=3.1, 16.8Hz), 2.54 (dd, 1H, J=9.6, 16.8Hz), 1.35 (t, 3H, J=7.2Hz), 1.34 (t, 3H,
J=7.2Hz), 1.25 (t, 3H, J=7.2Hz). 13C NMR (CDCl3, 100.6MHz) 6 171.22(s), 161.89(s),
152.90(s), 148.65(s), 63.33, 62.26, 61.43, 53.28, 41.24, 36.41, 14.91, 14.53, 14.50.
LRMS (MH+) 301.
1-Benzoyl-4-ethoxycarbonylmethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid ethyl
ester [721
To a stirred solution of 2-pyrazoline 64b (1.90g, 8.33mmol) in THF-1 20 (1:1, 20mL) at 0
C was added NaHCO3 (1.34 g, 16.0mmol). The mixture was stirred and cooled to 0C.
To this mixture was slowly added benzoyl chloride (1.29g, 9.17mmol). The resulting
mixture was stirred at R.T. overnight and extracted with CH 2 C12 (3x20 mL). The
combined organic layers were dried over Na2 SO 4 and solvents removed under vacuum.
The oily residue was purified by column chromatography on silica gel, with hexane/ethyl
acetate 85/15 and 65/35 as eluents, yielding the amide 72 (2.71g, 98% yield) as yellow oil.
'H NMR (CDCl 3, 400MHz) 6 7.92-7.90 (in, 2H), 7.52-7.40 (in, 3H), 4.43 (dd, 11H,
J=12.0, 12.6Hz), 4.32 (q, 2H, J=7.1Hz), 4.17 (q, 2H, J=7.2Hz), 4.03 (dd, 1H, J=7.2,
12.6Hz), 3.84-3.76 (in, 1H), 3.00 (dd, 1H, J=3.6, 16.8Hz), 2.66 (dd, 1H, J=9.6, 16.8Hz),
1.33 (t, 3H, J=7.2Hz), 1.26 (t, 3H, J=7.2Hz). 13C NMR (CDCl3, 100.6MHz) 6 170.79(s),
167.84(s), 161.47(s), 149.79(s), 132.74(s), 131.69, 130.13, 127.91, 61.95, 61.17, 52.69,
40.00, 36.14, 14.16, 14.11. LRMS (MH+) 333.
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1-Acetyl-4-ethoxycarbonylmethyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid ethyl
ester [731 2-Pyrazoline 64b (1.8 g, 7.9mmol) was treated with acetyl chloride (0.7g,
8.9mmol) in THF-H 20 (1:1, 20mL) as described for 72 to furnish the amide 73 (1.96g,
92% yield) as yellow oil. 1H NMR (CDCl 3, 400MHz) 6 4.29 (q, 2H, J=7.1Hz), 4.17-4.12
(m, 1H), 4.08 (q, 2H, J=7.1Hz), 3.77-3.66 (in, 2H), 2.89 (dd, 1H, J=3.2, 16.8Hz), 2.52
(dd, 1H, J=9.2, 16.8Hz), 2.13 (s, 3H), 1.31 (t, 3H, J=7.OHz), 1.19 (t, 3H, J=7.0Hz). 13C
NMR (CDCl 3, 100.6MHz) 6 170.71(s), 170.48(s), 161.29(s), 148.94(s), 61.97, 61.11,
51.31, 40.74, 36.14, 21.28, 14.13, 14.11. LRMS (MH+) 271.
4-Ethoxycarbonylmethyl-3-hydroxymethyl-4,5-dihydro-pyrazole-1-carboxylic acid
benzyl ester [80]
To a stirred solution of the 2-pyrazoline 64d (1.01 g, 2.79mmol) in 20ml of 1:1 solution of
THF/CH 30H at room temperature was added sodium borohydride (116mg, 3.07mmol)
The reaction mixture was stirred for 7h, till TLC analysis showed complete
disappearance of the starting material. The reaction was then carefully hydrolyzed with
saturated aqueous ammonium chloride solution (15m1). The resulting mixture was
extracted with ethyl acetate. The combined organic extracts were washed with saturated
aqueous sodium bicarbonate solution and brine, dried over Na2SO 4, filtered and
concentrated by rotary evaporation. The residue was purified by column chromatography
on silica gel, with hexane/ethyl acetate 80/20, 65/35, 50/50 and 20/80 as eluents, to give
the alcohol 80 (277mg, 31% yield) as yellow oil. 1H NMR (CDC13, 400MHz) 6 7.31-7.19
(m, 5H), 5.13 (s, 2H), 4.32 (d, lH, J= 14.6Hz), 4.25 (d, 1H, J= 14.8Hz), 4.09-3.98 (in,
3H), 3.60-3.50 (m, 2H), 2.72 (dd, 1H, J=4.4, 16.6Hz), 2.40 (dd, 1H, J=8.8, 16.6Hz), 1.25
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(t, 3H, J=7.1Hz) "C NMR (CDCl 3, 100.6MHz) 6 171.24(s), 160.06 (s), 152.92(s),
13 6 .03(s), 128.50, 128.28, 128.26, 67.63, 61.13, 58.60, 51.46, 41.83, 35.69, 14.09.
HRMS (DCI) calculated for C16H21N205 (MH}) 321.1450; found 321.1461.
4
-Ethoxycarbonylmethyl-4,5-dihydro-pyrazole-1,3-dicarboxylic acid 1-benzyl ester
3-methyl ester [81] The 2-pyrazoline 64d was treated with NaBH 4 as described for 80 to
give 81 (311mg, 32% yield) as light yellow powder, m.p. 98-100 C. H NMR (CDCl 3,
400MHz) 6 7.31-7.27(m, 5H), 5.30-5.23 (m, 2H), 4.25-4.17 (m, 1H), 4.11 (q, 2H,
J=7.1Hz), 3.83 (s, 3H), 3.81-3.72 (m, 2H), 2.96 (dd, 1H, J=3.2, 16.8Hz), 2.53 (dd, 1H,
J=9.6, 16.8Hz), 1.21(t, 3H, J=7.1Hz) 13C NMR (CDC13, 100.6MHz) 6 171.21(s), 161.90
(s), 152.32(s), 148.16(s), 135.63(s), 128.50, 128.46, 128.39, 68.26, 61.01, 52.95, 52.49,
40.92, 35.93, 14.09. LRMS (MH+) 349.
4-Ethoxycarbonylmethyl-3-formyl-4,5-dihydro-pyrazole-1-carboxylic acid benzyl
ester [84]
A solution of superhydride (1.OM in THF, 1.OmL, 1.0 mol) was added dropwise to a
solution of the 2-pyrazoline 64d (329mg, 0.91mmol) in the dry CH 2Cl 2 (10mL) at -78*C.
The resulting mixture was stirred for 4.5h at -78*C, till TLC analysis showed complete
disappearance of the starting material. The reaction was then hydrolyzed with 1M NaOH
(5 mL) and the organic residue extracted with CH 2Cl 2 (3x15 mL). The combined organic
layers were dried over Na2SO 4 and solvents removed under vacuum. The oily residue was
purified by column chromatography on silica gel, with hexane/ethyl acetate 85/15, 65/35
and 50/50 as eluents, yielding the aldehyde 84 (121mg, 42% yield) as yellow oil; 1H
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NMR (CDC13, 400MHz) 69.81 (s, 111), 7.43-7.32 (m, 5H), 5.33 (d, 1H, J= 12.4Hz), 5.30
(d, 1H, J= 12.8Hz), 4.28 (t, 1H, J= 11.3Hz), 4.14(q, 2H, J=7.2Hz), 3.85-3.72 (in, 2H),
2.99 (dd, 1H, J=3.3, 17.0Hz), 2.53 (dd, 1H, J=9.4, 16.9Hz), 1.24 (t, 3H, J=7.1Hz) 13 C
NMR (CDCl 3, 100.6MHz) 6 187.41, 171.06(s), 155.77(s), 152.49(s), 135.65 (s), 129.04,
128.92, 69.07, 61.47, 54.16, 45.37, 35.74, 14.49. HRMS (DCI) calculated for
C16H 19N205 (MH) 319.1294; found 319.1303.
4
-Ethoxycarbony methy-3-ethoxycarbony oxymethy-4,5-dihydro-pyrazole- -
carboxylic acid benzyl ester [86]
A solution of superhydride (1.0M in THF, 0.36mL, 0.36mol) was added dropwise to a
solution of the 2-pyrazoline 64d (118.6mg, 0.33mmol) in the dry CH 2Cl 2 (10mL) at -
78 C. The reaction mixture was stirred for 20min at -780C and a solution of superhydride
(1.0M in THF, 0.2mL, 0.2mmol) was added dropwise. The resulting mixture was allowed
to warm to room temperature overnight, till TLC analysis showed complete
disappearance of the starting material. The reaction was then hydrolyzed with 1M NaGH
(5 mL) and the organic residue extracted with CH 2Cl 2 (3x10mL). The combined organic
layers were dried over Na2SO 4 and solvents removed under vacuum. The oily residue was
dissolved in acetonitrile (5ml). To this solution was added aqueous saturated K 2CO3
(3mL) and C1COOEt (2equiv.). The reaction was stirred overnight. The resulting
reaction mixture was extracted with methylene chloride. The combined organic extracts
were washed with brine, dried over Na2SO 4 , filtered and concentrated by rotary
evaporation. The resulting residue was purified by column chromatography on silica gel,
with hexane/ethyl acetate 85/15 and 70/30 as eluents, affording the pyrazoline 86 (21mg,
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16% yield starting from the pyrazoline 64d) as yellow oil; H NMR (CDC3, 400MHz) 6
7.44-7.33 (m, 5H), 5.28 (s, 2H), 4.98-4.90 (m, 2H), 4.24 (q, 2H, J=7.1Hz), 4.19-4.14 (m,
3H), 3.75-3.61 (in, 2H), 2.80 (dd, 1H, J=4.2, 16.6Hz), 2.52 (dd, 1H, J=9.3, 16.6Hz), 1.33
(t, 3H, J=7.1Hz), 1.27 (t, 3H, J=7.1Hz) '3C NMR (CDCl 3 100.6MHz) 6 171.03(s),
155.02 (s), 154.50(s), 153.12(s), 136.37(s), 128.92, 128.77, 128.70, 68.24, 65.12, 63.24,
61.58, 52.14, 42.19, 35.95, 14.59, 14.50. HRMS (DCI) calculated for C19 H2sN 2 O7 (MH)
393.1662; found 393.1657.
4
-Ethoxycarbonylmethyl-3-formyl-4,5-dihydro-pyrazole-1,5-dicarboxylic acid 1-
benzyl ester 5-ethyl ester [89] A solution of superhydride (1.OM in THF, 0.44mL,
0.44imol) was added dropwise to a solution of the 2-pyrazoline 66c (174mg, 0.4mmol)
in the dry CH2Cl 2 (10mL) at -78 C. The resulting mixture was stirred for 5h at -78"C, till
TLC analysis showed complete disappearance of the starting material. The reaction was
then hydrolyzed with 1M NaGH (5 mL) and the organic residue extracted with CH 2Cl 2
(3x15mL). The combined organic layers were dried over Na2 SO 4 and solvents removed
under vacuum. The oily residue was purified by column chromatography on silica gel,
with hexane/ethyl acetate 85/15, 65/35 and 50/50 as eluents, yielding the aldehyde 89
(53mg, 34% yield) as yellow oil; 1H NMR (CDCl 3, 400MHz) 6 9.82 (s, 1H), 7.40-7.33
(m, 5H), 5.40-5.28 (m, 2H), 4.73 (d, 1H, J= 5.9Hz), 4.15 (q, 4H, J=7.1Hz), 3.82-3.76 (m,
1H), 2.90 (dd, 1H, J=3.9, 16.6Hz), 2.73 (dd, 1H, J=8.5, 16.7Hz), 1.24 (t, 6H, J=7.1Hz)
13C NMR (CDCl, 100.6MHz) 6 186.86, 170.09, 168.93(s), 153.78 (s), 135.33 (s), 129.07,
129.03, 128.90, 69.46, 66.64, 62.70, 61.69, 45.37, 35.37, 14.46, 14.34. HRMS (DCI)
calculated for C19H2 3N2 0 7 (MH+) 391.1505; found 391.1511.
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3
-Dimethoxymethyl-4-ethoxycarbonylmethyl-4,5-dihydro-pyrazole-1-carboxylic
acid benzyl ester [90]
Method A: The aldehyde 84 (126mg, 0.396mmol) was dissolved in methanol (5mi) and
2, 2-dimethoxypropane (90.8mg, 0.872mmol) was added while stirring. The stirred
solution is cooled to 00C, then 15mg of p-toluenesulfonic acid monohydrate is added and
the mixture is stirred at room temperature for 19h. After the volatile material is removed
on a rotary evaporator, the remaining yellow oil is neutralized with 10 mL of aqueous
saturated sodium bicarbonate solution and diluted with 15 mL of methylene chloride. The
aqueous layer is separated and extracted with methylene chloride. The combined organic
layers are washed with brine, dried over Na2SO 4 and concentrated by rotary evaporation.
The residual yellow oil is purified by column chromatography on silica gel, with
hexane/ethyl acetate 70/30 as the eluent, yielding the dimethyl acetal 90 (40.4mg, 28%
yield) as a yellow oil. Method B: The carbonyl compound 84 (92.4mg, 0.29mmol) was
dissolved in methanol (4 mL), and bismuth nitrate (14.1mg, 0.029mmol) was added while
stirring. After the starting material was consumed as indicated by TLC, the methanol was
evaporated. The crude product was extracted with methylene chloride, washed with
aqueous saturated sodium bicarbonate solution, and dried over Na2SO 4 , and the solvent
was evaporated. The residual yellow oil is purified by column chromatography on silica
gel, with hexane/ethyl acetate 70/30 as the eluent, yielding the dimethyl acetal 90
(30.7mg, 29% yield) as a yellow oil. lH NMR (CDCl 3 400MHz) 7.42-7.28 (m, 5H),
5.30-5.26 (m, 2H), 4.98 (s, 1H), 4.18-4.10 (m, 311), 3.70-3.62 (m, 2H), 3.42 (s, 3H), 3.41
(s, 3H), 3.02 (dd, 1H, J=2.8, 17.2Hz), 2.46 (dd, 1H, J=9.9, 17.2Hz), 1.24 (t, 3H, J=7.2Hz)
90
13C NMR (CDC13, 100.6MHz) 6 171.70(s), 156.43(s), 153.27(s), 136.52(s), 128.88,
128.74, 128.63, 68.06, 61.22, 55.87, 55.84, 52.37, 40.97, 36.39, 14.54. HRMS (DCI)
calculated for C18H2 5N20 6 (MH+) 365.1713; found 365.1707.
3-[1, 3] Dioxolan-2-y-4-ethoxycarbonylmethyl-4,5-dihydro-pyrazole-l-carboxylic
acid benzyl ester [91]
A 25mL round-bottomed flask was charged with the aldehyde 84 (235.7mg, 0.74mmol),
benzene (10mL), 1, 2-ethanediol (92mg, 1.48mmol) and 15mg of p-toluenesulfonic acid
monohydrate. The flask is attached to a water separator (Dean-Stark trap) and a reflux
condenser fitted with a drying tube. The reaction mixture is refluxed for 7h until the
starting material was consumed as indicated by TLC. The reaction mixture is cooled to
room temperature, extracted successively with 1M sodium hydroxide solution and water,
dried over Na2SO 4, and the solvent was evaporated. The residual yellow oil is purified by
column chromatography on silica gel, with hexane/ethyl acetate 65/35 as the eluent,
yielding the cyclic acetal 91 (129mg, 48% yield) as yellow oil. 1H NMR (CDCl 3,
400MHz) 6 7.43-7.33 (in, 5H), 5.59 (s, 1H), 5.32-5.25(m, 2H), 4.19-3.92 (in, 7H), 3.76-
3.66 (in, 2H), 2.89 (dd, 1H, J=3.5, 17.2Hz), 2.49 (dd, 1H, J=10.0, 17.1Hz), 1.27 (t, 3H,
J=7.2Hz) 13C NMR (CDCl 3, 100.6MHz) 6 171.57(s), 155.76(s), 153.18(s), 136.42(s),
128.91, 128.76, 128.67, 100.26, 68.20, 65.99, 65.71, 61.35, 52.89, 40.43, 36.79, 14.54.
HRMS (DCI) calculated for C18H23 N20 6 (MH+) 363.1556; found 363.1545.
3-Hydroxymethyl-4-methoxycarbonylmethyl-4,5-dihydro-pyrazole-1-carboxylic
acid benzyl ester [921
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The 2 -pyrazoline 64d was treated with NaBH 4 as described for 80 to give 92 ( 35mg, 4%
yield) as colorless oil. 1H NMR (CDCl 3, 400MHz) 6 7.43-7.28 (in, 5H), 5.17 (s, 2H), 4.44
(d, 1H, J= 14.6Hz), 4.38 (d, II, J= 14.6Hz), 4.19-4.12 (m, 1H), 3.72 (s, 3H), 3.70-3.63
(in, 2H), 2.82 (dd, 1H, J=5.0, 16.8Hz), 2.55 (dd, 1H, J=8.2, 16.8Hz). 13C NMR (CDCl1,
100.6MHz) 6 171.71(s), 159.33 (s), 152.88(s), 136.05(s), 128.52, 128.35, 128.29, 67.72,
58.94, 52.19, 51.69, 41.71, 35.67. LRMS (MH+) 307.
4
-(2 -Hydroxy-ethyl)-3-hydroxymethyl-4,5-dihydro-pyrazo e-1-carboxylic acid
benzyl ester [93] To a stirred solution of the 2-pyrazoline 64d (2.08g, 5.71mmol) in
40ml of 1:1 solution of THF/CH3OH at room temperature was added sodium borohydride
(1.74g, 45.9mmol) The reaction mixture was stirred at 0 "C for 5h, utill TLC analysis
showed complete disappearance of the starting material. The reaction was then carefully
hydrolyzed with saturated aqueous ammonium chloride solution (30m1). The resulting
mixture was extracted with ethyl acetate. The combined organic extracts were washed
with saturated aqueous sodium bicarbonate solution and brine, dried over Na2SO 4,
filtered and concentrated by rotary evaporation. The residue was purified by column
chromatography on silica gel, with hexane/ethyl acetate 20/80, ethyl acetate/methanol
90/10, ethyl acetate/methanol 70/30 as eluents, to give the diol 93 (0.559g, 35% yield) as
yellow oil. 1H NMR (CDCl 3, 400MHz) 6 7.39-7.32 (m, 5H), 5.24 (s, 2H), 4.45-4.35 (in,
2H), 4.02 (t, 1H, J=11.0Hz), 3.76-3.71 (in, 1H), 3.66-3.61 (in, 2H), 3.48-3.40 (in, 1H),
2.00-1.96 (m, 1H), 1.71-1.68 (m, 1H). 13C NMR (CDCl 3, 100.6MHz) 6 162.51(s),
153.21(s), 136.00(s), 128.54, 128.30, 128.20, 67.66, 59.72, 58.35, 51.07, 42.68, 33.55.
HRMS (DCI) calculated for C14H19N2 4 (MH) 279.1345; found 279.1347.
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3
-(tert-Butyl-dimethyl-silanyloxymethyl)-4-ethoxycarbonylmethyl-4,-dihydro 
-
pyrazole-l-carboxylic acid benzyl ester [941
TBDMSC1 (167.0mg, 1.11 mmol) and imidazole (75.3mg, 1.11 mmol) were successively
added at R.T. to a solution of the corresponding alcohol 80 (102.5mg, 0.32 mmol) in
CH 2Cl 2 (5 mL) and the resulting mixture stirred at R.T. for 3h, utill TLC analysis showed
complete disappearance of the starting material. The reaction was hydrolyzed with H2 0
(5 mL) and the organic residue extracted with CH 2Cl 2 (3x5 mL). The combined organic
layers were dried over Na2SO 4 and solvents removed under vacuum. The oily residue was
purified by column chromatography on silica gel, using as eluent hexane/ethyl acetate
90/10 and 70/30, yielding the corresponding silyl ethers 94 (123.5mg, 90%) as yellow oil.
'H NMR (CDCl 3, 400MHz) 8 7.33-7.19 (m, 5H), 5.17 (s, 2H), 4.39 (d, 1H, J= 24.0Hz),
4.36 (d, 1H1, J= 24.0Hz), 4.08-3.99 (m, 3H), 3.62-3.53 (in, 2H), 2.80 (dd, 1H, J=3.4,
16.6Hz), 2.37 (dd, 1H, J=9.8, 16.6Hz), 1.15 (t, 3H, J=7.0Hz), 0.80 (s, 9H), 0.00 (s, 3H),
0.01 (s, 3H) 13C NMR (CDCl 3, 100.6MHz) 6 171.00(s), 159.32 (s), 152.91(s), 136.25(s),
128.48, 128.28; 128.15, 67.55, 60.95, 59.70, 51.35, 41.93, 35.56, 25.73, 18.14(s), 14.11, -
5.48, -5.54. HRMS (DCI) calculated for C22H35N2O5Si (MH+) 435.2315; found 435.2330.
4, 5-Dihydro-pyrazole-,3-dicarboxylic acid 1-benzyl ester 3-ethyl ester [951
Yellow solid; m.p. 88-91 *C, 93% yield. 'H NMR (CDCl 3; 400MHz) 6 7.45-7.33 (in, 5H),
5.31 (s, 2H), 4.35 (q, 2H, J=7.1Hz), 4.02 (t, 211, J=10.8Hz), 3.11 (t, 211, J=10.8Hz), 1.36
(t, 3H, J=7.1Hz). 13C NMR (CDCl 3, 100.6MHz) 6 161.77 (s), 152.60 (s), 148.26 (s),
135.80 (s), 128.51, 128.44, 128.36, 68.15, 61.84, 46.72, 31.59, 14.17. LRMS (MH+) 277.
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3
-Hydroxymethyl-4,5-dihydro-pyrazole-1-carboxylic acid benzyl ester 1961
To a stirred solution of the 2-pyrazoline 95 (2.03g, 7.35 mmol) in 20ml of 1:1 solution of
THF/CH 30H at room temperature was added sodium borohydride (835mg, 22.1n ol)
The reaction mixture was stirred for 5h, utill TLC analysis showed complete
disappearance of the starting material. The reaction was then carefully hydrolyzed with
saturated aqueous ammonium chloride solution (15ml). The resulting mixture was
extracted with ethyl acetate. The combined organic extracts were washed with saturated
aqueous sodium bicarbonate solution and brine, dried over Na2SO 4, filtered and
concentrated by rotary evaporation. The residue was purified by column chromatography
on silica gel, with hexane/ethyl acetate 70/30 and ethyl acetate/methanol 95/5 as eluents,
to give the alcohol 96 (1.31 g, 76% yield) as yellow oil. 'H NMR (CDCl 3 400MHz) 6
7.42-7.27 (m, 5H), 5.26 (s, 2H), 4.38(s, 2H), 3.89 (t, 2H, J=10.2Hz), 2.91 (t, 2H,
J=10.2Hz); 13C NMR (CDCl 3, 100.6MHz) 8 159.98 (s), 153.06(s), 136.16(s), 128.54,
128.47, 128.28, 67.57, 59.76, 45.17, 31.93. HRMS (DCI) calculated for C12H15N2 0 3
(MH+) 235.1083; found 235.1077.
3-(tert-Butyl-dimethyl-silanyloxymethyl)-4,5-dihydro-pyrazole-1-carboxylic acid
benzyl ester 197]
TBDMSCl (1.01g, 6.70nmol) and imidazole (0.458g, 6.73mmol) were successively
added at R.T. to a solution of the corresponding alcohol 96 (0.450g, 1.92mmol) in
CH 2Cl 2 (15 mL) and the resulting mixture stirred at R.T. overnight, utill TLC analysis
showed complete disappearance of the starting material. The reaction was hydrolyzed
with H 20 (15 mL) and the organic residue extracted with CH 2Cl 2 (3x25 mL). The
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combined organic layers were dried over Na2 SO 4 and solvents removed under vacuum.
The oily residue was purified by colunm chromatography on silica gel, using as eluents
hexane/ethyl acetate 90/10 and 70/30, yielding the corresponding silyl ethers 97 (0.482g,
72%) as yellow oil. 1H NMR (CDCl 3, 400MHz) 6 7.34-7.19 (in, 5H), 5.18 (s, 2H), 4.35 (s,
2H), 3.79 (t, 2H, J=10.2Hz), 2.85 (t, 2H, J=10.2Hz), 0.81 (s, 9H), 0.00 (s, 6H); 13C NMR
(CDCl 3, 100.6MHz) 6 159.50 (s), 153.03(s), 136.37(s), 128.46, 128.25, 128.13, 67.45,
60.59, 44.97, 32.46, 25.76, 18.21(s), -5.41. HRMS (DCI) calculated for C1 8 H2 9N2 O3Si
(MH+) 349.1947; found 349.1942.
3
-(tert-Butyl-dimethyl-silany oxymethyl)-pyrazolidine-1,2-dicarboxylic acid
dibenzyl ester [98]
A solution of superhydride (1.0M in THF, 4.1 mL, 4.1 mol) was added dropwise to a
stirred solution of the silyl ether 97 (573.8mg, 1.65mmol) in the dry CH 2Cl 2 (15mL) at -
78 C. The resulting mixture was allowed to warm to room temperature overnight, till
TLC analysis showed complete disappearance of the starting material. The reaction was
then hydrolyzed with 1M NaOH (15mL) and the organic residue extracted with CH 2C12
(3x20mL). The combined organic layers were dried over Na2 SO 4 and solvents removed
under vacuum. The oily residue was dissolved in methylene chloride (15ml). To this
solution was added H20 (15mL), NaHCO 3 (2equiv.) and CbzCl (2equiv.). The reaction
was stirred overnight. The resulting reaction mixture was extracted with methylene
chloride. The combined organic extracts were washed with brine, dried over Na2SO 4,
filtered and concentrated by rotary evaporation. The resulting residue was purified by
column chromatography on silica gel, with hexane/ethyl acetate 85/15 and 70/30 as
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eluents, affording the pyrazolidine 98 (590mg, 74% yield starting from the silyl ether 97)
as light yellow liquid; 'H NMR (CDCl 3, 400MHz) 6 7.37-7.26 (in, 10H), 5.20-5.12 (in,
411), 4.29 (in, 1H), 4.15-4.08 (in, 1H); 3.79 (dd, 1H, J= 4.4, 10.2Hz), 3.47 (dd, 1H, J= 7.2,
10.211z), 3.24 (dd, 1H, J=8.6, 19.4Hz), 2.17-2.13 (in, 111), 2.10-2.01 (in, 111), 0.86 (s,
9H), 0.01 (s, 3H), 0.00 (s, 31). 13C NMR (CDCl3 100.6MHz) 6 157.01 (s), 156.91(s),
136.11(s), 136.00 (s), 128.49, 128.46, 128.09, 128.05, 127.80, 127.76, 67.95, 67.90,
64.56, 60.16, 47.00, 28.62, 25.84, 18.25, -5.47, -5.53. HRMS (DCI) calculated for
C26H37N20 5Si (MH) 485.2472; found 485.2477.
3
-Benzyloxycarbonyloxymethyl-4-ethoxycarbonylethylpyrazolidine-1,2
dicarboxylic acid dibenzyl ester [99]
To a solution of the 2-pyrazoline 80 (102.3mg, 0.32mmol) in glacial acetic acid (5m1)
was added NaCNBH 3 (121mg, 1.93mmol). The reaction was stirred at R.T. for 6h, at
which time the reaction mixture was diluted with ethyl acetate and quenched by addition
of a saturated aqueous solution of potassium carbonate. The organic layer was washed
with brine and dried over Na2SO 4. Solvent was removed by rotary evaporation and the
resulting residue dissolved in methylene chloride (5ml). To this solution was added H20
(5mL), NaHCO3 (2equiv.) and CbzCl (2equiv.). The reaction was stirred overnight. The
resulting reaction mixture was extracted with methylene chloride. The combined organic
extracts were washed with brine, dried over Na2SO 4, filtered and concentrated by rotary
evaporation. The resulting residue was purified by colunm chromatography on silica gel,
with hexane/ethyl acetate 85/15, 70/30 and 50/50 as eluents, affording the pyrazolidine
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99 (19mg, 10% yield from the 2-pyrazoline 80) as yellow oil. 1H NMR (CDCl 3, 400MHz)
6 7 .4 0-7.25(m, 15H), 5.24-5.06(m, 6H), 4.40(dd, 1H, J=8.0, 11.2Hz), 4.34-4.29(m, 1H),
4.26-4.21(m, 2H), 4.14(q, 2H, J=7.2Hz), 2.97(d, 1H, J=8.6, , 11.4Hz), 2.81-2.71(m, 1H),
2.54(dd, 1H, J=6.8, 16.6Hz), 2.42(dd, 1H, J=7.6, 16.6Hz), 1.26(t, 3H, J=7.0Hz). 13C
NMR (CDCl 3, 100.6MHz) S 170.88(s), 156.88(s), 156.46(s), 154.72(s), 135.86(s),
135.73(s), 135.02(s), 128.60, 128.52, 128.47, 128.42, 128.19, 128.03, 127.82, 127.60,
69.85, 68.25, 68.12, 67.81, 62.57, 61.02, 52.29, 38.77, 36.91, 14.14. HRMS (DCI/NH 3)
calculated for C32H35N209 (MH) 591.2343; found 591.2319.
4
-Ethoxycarbonylmethyl-3-hydroxymethyl-pyrazolidine-, 2-dicarboxylic acid
dibenzyl ester [100]
The 2-pyrazoline 80 (102.3mg, 0.32mmol) was treated with NaCNBH 3 (121mg,
1.93mmol) in glacial acetic acid (5ml) followed by the treatment of the crude product
with CbzCl as described for 99 to afford the pyrazolidine 100 (57mg, 39% starting from
the 2-pyrazoline 80) as light yellow oil. 'H NMR (CDC13, 400MHz) 6 7.39-7.34 (in, iGH),
5.26-5.12 (m, 4H), 4.36 (dd, 1H, J=7.6, 11.6Hz), 4.15 (q, 2H, J=7.2Hz), 4.02-3.99 (m,
1H), 3.85-3.82 (m, 1H), 3.52-3.48 (m, 1H), 2.97 (dd, 1H, J=9.6, 11.6Hz), 2.79-2.70 (m,
1H), 2.53 (dd, 1H, J=6.2, 16.2Hz), 2.41 (dd, 1H, J=8.2, 16.2Hz), 1.26 (t, 3H, J=7.2Hz).
13C NMR (CDCl 3, 100.6MHz) 6 171.04(s), 157.62(s), 156.79(s), 135.72(s), 135.51(s),
128.64, 128.57, 128.44, 128.27, 128.07, 127.87, 68.59, 68.25, 66.16, 62.33, 60.99, 53.12,
37.90, 36.17, 14.15. HRMS (DCI/NH3) calculated for C24H29N207 (MH) 457.1975;
found 457.1956.
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S-Oxo-hexahydro-pyrano[3,4-c]pyrazole-1,2-dicarboxylic acid dibenzyl ester [1011
The 2 -pyrazoline 80 (102.3mg, 0.32mmol) was treated with NaCNBH 3 (121mg,
1. 9 3mmol) in glacial acetic acid (5mi) followed by the treatment of the crude product
with CbzCl as described for 99 to afford the pyrazolidine 101 (14mg, 11% starting from
the 2-pyrazoline 80) as light yellow oil. H NMR (CDC 3, 400MHz) 6 7.32-7.22 (m, 10H),
5.14-5.03 (m, 4H), 4.57 (dd, 1H, J=7.6, 13.6Hz), 4.38 (dd, 1H, J=5.2, 12.0Hz), 4.00-3.94
(m, 1H), 3.34 (dd, 1H, J=7.6, 12.0Hz), 3.00-2.92 (m, 1H), 2.52 (dd, 1H, J=6.4, 15.5Hz),
2.25 (dd, 1H, J=8.6, 15.5Hz); "C NMR (CDCl 3 100.6MHz) 6 170.28(s), 156.85(s),
155.83(s), 135.45(s), 135.42(s), 128.62, 128.56, 128.42, 128.33, 127.96, 68.79, 68.52,
67.48, 55.50, 52.79, 36.89, 32.20. HRMS (DCI/NH 3) calculated for C22H23N206 (MH+)
411.1556; found 411.1554.
4
-Ethoxycarbonylmethyl-pyrazolidine-1,2,3-tricarboxylic acid 1-benzyl ester 2,3-
diethyl ester [1021
To a solution of the 2-pyrazoline 69f (110mg, 0.37mmol) in glacial acetic acid (5m1) was
added NaCNBH 3 (140mg, 2.23mmol). The reaction was stirred at R.T. for 5h, at which
time the reaction mixture was diluted with ethyl acetate and quenched by addition of a
saturated aqueous solution of potassium carbonate. The organic layer was washed with
brine and dried over Na2SO 4. Solvent was removed by rotary evaporation and the
resulting residue dissolved in methylene chloride (5ml). To this solution was added H20
(5mL), NaHCO 3 (2equiv.) and CbzCl (2equiv.). The reaction was stirred overnight. The
resulting reaction mixture was extracted with methylene chloride. The combined organic
extracts were washed with brine, dried over Na2SO 4, filtered and concentrated by rotary
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evaporation. The resulting residue was purified by colunm chromatography on silica gel,
with hexane/ethyl acetate 85/15, 70/30 and 50/50 as eluents, affording the pyrazolidine
102 (66mg, 41% yield from the 2-pyrazoline 69) as yellow liquid; 11 NMR (CDCl 3,
400MHz) 6 7.35-7.23 (m, 511), 5.22 (d, 1H, J=12.8Hz), 5.11 (d, 1H1, J=12.8Hz), 4.43 (br.s,
1H), 4.30 (br.s, 11), 4.22-4.07 (m, 6H), 2.97 (m, 2H), 2.59 (dd, 1H, J=3.6, 16.2Hz), 2.42
(dd, 1H, J=6.0, 16.2Hz), 1.23-1.15 (in, 9H); 3C NMR (CDCl 3 100.6MHz) 6 170.59(s),
169.94(s), 156.93(s), 156.21(s), 135.99(s), 128.42, 128.06, 127.72, 68.09, 64.65, 63.04,
61.73, 61.06, 51.91, 40.95, 36.52, 14.34, 14.13, 14.02. HRMS (DCI/NH3) calculated for
C21H29N20g (MH+) 437.1924; found 437.1921.
3
-Trimethylsilanyl-4,5-dihydro-pyrazole-1,5-dicarboxylic acid 1-benzyl ester 5-
methyl ester [110b]
Light yellow oil; 12% yield starting from acryloyl choride. 1H NMR (CDC 3, 400MHz) 6
7.40-7.25 (m, 5H), 5.35 (d, 11H, J= 12.6Hz), 5.22 (d, 1H, J= 12.6Hz), 4.64 ( dd, 11H, J=6.4,
12.4Hz), 3.66 (br. s, 3H), 3.23 (dd, 11H, J=12.4, 18.0Hz), 2.96 (dd, 11H, J=6.0, 18.0Hz),
0.26 (s, 9H); 13C NMR (CDCl3, 100.6MHz) 6 173.55 (s), 164.14 (s), 154.66 (s), 138.47
(s), 130.73, 130.48, 130.42, 69.95, 59.17, 54.77, 45.73, 0.00. HRMS (DCI / NH3) calcd
for C16H23N2 0 4 Si (MH) 335.1427; found 335.1422.
1-Benzyl 5-methyl 1H-pyrazole-1, 5(41,5H)-dicarboxylate [110c]
Yellow oil; 8% yield starting from acryloyl choride. 'H NMR (CDCl 3, 400MHz) 6 7.31-
7.20 (m, 5H), 6.77 (s, 1H), 5.24 (d, 1H, J= 12.4Hz), 5.13 (d, 1H, J= 11.6Hz), 4.66 (dd,
1H, J=5.8, 12.4Hz), 3.61 (bs, 311), 3.17 (ddd, 1H, J=1.3, 12.4, 18.4Hz), 2.89 (ddd, 11H,
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J=1.6, 6.0, 18.4Hz) "C NMR (CDCl 3, 100.6MHz) 6 169.24 (s), 151.23 (s), 143.22,
134.53 (s), 127.18, 126.97, 126.95, 66.65, 55.56, 51.33, 37.75. HRMS (DCI / NH3 ) caled
for C13Hj5N20 4 (MH+) 263.1032; found 263.1027.
S-Trimethylsilanyl-4,5-dihydro-pyrazole-1,3-dicarboxylic acid l-benzyl ester 3-tert-
butyl ester [IlHa] Yellow oil; 'H NMR (CDC 3, 400MHz) 6 7.45-7.30 (in, 5H), 5.34 (d,
1H, J= 12.1Hz), 5.25 (d, 1H, J= 12.2Hz), 3.76 ( dd, 1H, J=11.9, 13.5Hz), 3.28 ( dd, 1H,
J=13.6, 18.3Hz), 2.90 ( dd, 1H, J=11.8, 18.3Hz), 1.56 (s, 9H), 0.12 (s, 9H); 13 C NMR
(CDCl 3, 100.6MHz) 8 161.57(s), 153.72(s), 149.46 (s), 136.31(s), 128.86, 128.80, 128.66,
83.39(s), 68.37, 50.83, 35.82, 28.42, -2.24. LRMS (MH+) 377. HRMS (DCI / NH3) found
375. Product has oxidized.
3-Trimethylsilanyl-4, 5-dihydro-pyrazole-1, 5-dicarboxylic acid l-benzyl ester 5-
tert-butyl ester [111b]
Yellow oil; 'H NMR (CDCl 3, 400MHz), 6 7.16-7.02 (n, 5H), 5.01 (br. s, 2H), 4.25 (dd,
1H, J=5.7, 12.3Hz), 2.95 (dd, 1H, J=12.3, 17.9Hz), 2.65 (dd, 1H, J=5.6, 18.0Hz), 1.12 (s,
9H), 0.00 (s, 9H); 13 C NMR (CDCl3 100.6MHz) 6 172.10, 164.06, 154.83, 138.51,
130.73, 130.46, 130.39, 84.36, 69.82, 60.05, 45.89, 30.10, 0.00. HRMS (M+) calculated
for C,9H28O4N 2Si: 376.181836, found: 376.183081.
4,5-Dihydro-pyrazole-1,5-dicarboxylic acid 1-benzyl ester 5-tert-butyl ester [111c]
Yellow oil; 'H NMR (CDCl3, 400MHz) 6 7.38-7.24 (m, 5H), 6.80 (s, 1H), 5.27-5.20 (m,
2H), 4.57 (dd, 1H, J=5.6, 12.5Hz), 3.19 (dd, 1H, J=12.6, 18.4Hz), 2.88 (dd, 1H, J=5.6,
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18 .6Hz), 1.37 (s, 9H); 1C NMR (CDCl 3, 100.6MHz) S 169.52 (s), 152.93 (s), 144.95,
136.32 (s), 128.84, 128.63, 128.57, 82.80 (s), 68.13, 58.02, 39.54, 28.15. HRMS (DCI /
NH3) calcd for C, 6H2 1N20 4 (MH+) 305.1501; found 305.1492.
3, 4 -Dihydro-2H-pyrazole-3-carboxylic acid tert-butyl ester [111d]
Yellow oil; 1H NMR (CDCl 3a 400MHz) 7.0 (s, 1H), 4.02 (dd, 1H, J=4.9, 11.0Hz), 2.93
(dd, 1H, J=1.7, 5.0Hz), 2.90 (dd, 1H, J=1.4, 11.2Hz), 1.39 (s, 9H); 13C NMR (CDC 3,
100.6MHz) 6 172.41(s), 143.10, 82.59 (s), 59.45, 37.83, 28.25. HRMS (DCI / NH3)
caled for CsH 5N2O2 (MH+) 171.1134; found 171.1130.
4
-MethyI-5-trimethylsilanyl-4,5-dihydro-pyrazole-l,3-dicarboxylic acid 1-benzyl
ester 3-ethyl ester [112a]
Yellow oil; 'H NMR (CDC13, 400MHz) 6 7.41-7.26 (m, 5H), 5.31 (d, 1H, J 12.2Hz),
5.23 (d, 1H, J= 12.2Hz), 4.30 ( q, 2H, J=7.1Hz), 3.45 ( d, 1H, J=7.6Hz), 3.32 (quintet, 1H,
J=7.0Hz), 1.33 (t, 3H, J= 7.1Hz), 1.28 (d, 3H, J= 6.9Hz), 0.06 (s, 9H); 13C NMR (CDCl 3
100.6MHz) 6 162.15(s), 153.27 (s), 151.36 (s), 136.24 (s), 128.90, 128.85, 128.68, 68.46,
62.02, 59.30, 43.00, 20.44, 14.55, -2.61. HRMS (DCI / NH3) caled for C, 8H27N2O4Si
(MH+) 363.1740; found 363.1748.
4-Methyl-3-trimethylsilanyl-4,5-dihydro-pyrazole-1,5-dicarboxylic acid 1-benzyl
ester 5-ethyl ester [112b] Yellow oil; 'H NMR (CDCl 3 400MHz) 6 7.10-7.00 (m, 5H),
5.03-4.96 (m, 2H), 3.92 (d, 1H, J=5.3Hz), 3.84 (broad signal, 2H), 3.02-2.95 (m, 1H),
0.99 (d, 3H, J=7.3Hz), 0.89(broad signal, 3H), 0.00(s, 9H); 13C NMR (CDCl 3,
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100.6MHz) 6 171.88, 167.29, 154.02, 137.68, 130.24, 129.96, 129.62, 69.10, 66.60,
62.98, 53.62, 20.01, 15.58, 0.00. HRMS (M+) calculated for C18H26N20 4Si: 362.1662,
found: 362.1656.
4
-Methyl-4,5-dihydro-pyrazole-1,5-dicarboxylic acid 1-benzyl ester 5-ethyl ester
[112c]
Yellow oil; 1H NMR (CDCl 3, 400MHz) 6 7.37-7.27 (m, 5H), 6.76 (s, 1H), 5.30-5.17 (m,
211), 4.29 (d, 1H, J=5.6Hz), 4.14 (broad signal, 2H), 3.24 (m, 111), 1.27 (t, 3H, J= 7.2Hz),
1.19 (broad signal, 3H); 13C NMR (CDCl 3, 100.6MHz) 6 169.82(s), 152.65 (s), 149.19,
135.78(s), 128.59, 128.49, 128.27, 67.96, 64.72, 61.77, 47.20, 17.49, 14.00. HRMS (El)
calcd for C1sH 18N204(M+) 290.1267; found 290.1268.
4
-Methyl-5-trimethylsilanyl-2H-pyrazole-3-carboxylic acid ethyl ester [112d]
Yellow solid; m.p. >120'C; 6% yield; 11 NMR (CDCl 3, 400MHz) 4.30 (q, 2H, J =
7.1Hz), 2.36 (s, 3H), 1.24 (t, 3H, J = 7.1Hz), 0.29 (s, 9H). 13C NMR (CDCl 3, 100.6MHz)
6 163.6 (s), 142.3 (s), 141.1 (s), 127.3(s), 60.6, 14.6, 10.7, -1.2. HRMS (DCI) calculated
for C1oH19N2O2(MH+) 227.1216; found 227.1212.
4-Methyl-2H-pyrazole-3-carboxylic acid ethyl ester [112e]
Yellow solid; m.p. 152-155 C; 33% yield; 11 NMR (MeOH-d 4, 400MHz) 6 7.47 (s, 1),
4.34 (q, 2H, J = 7.1Hz), 2.26 (s, 3H), 1.36 (t, 3H, J = 7.1Hz) 13C NMR (MeOH-d 4,
100.6MHz) 6 161.2 (s), 141.1 (s), 129.7 (s), 120.3 (s), 60.6, 13.6, 8.7. HRMS (DCI /
NH 3) caled for C7H1 1N202(MH+) 155.0821; found 155.0816.
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4
-Methyl-pyrazole-1,5-dicarboxylic acid 1-beuzyl ester 5-ethyl ester [112g]
Yellow oil; 'H NMR (CDCl 3, 400MHz) 6 7.95 (s, 1H), 7.42-7.35 (m, 5H), 5.47 (s, 2H),
4.39 (q, 2H, J = 7.1Hz), 2.29 (s, 3H), 1.41 (t, 3H, J= 7.1Hz) 13C NMR (CDCl 3,
100.6MHz) 6 162.51 (s), 149.26 (s), 146.79 (s), 141.42 (s), 134.50 (s), 131.15, 129.39,
129.15, 128.89, 70.76, 61.76, 14.65, 10.05. HRMS (DCI / NH3) ealed for C15H 17N2 0 4
(MH+) 289.1188; found 289.1189.
4
-Methyl-3-trimethylsilanyl-pyrazole-1,5-dicarboxylic acid 1-benzyl ester 5-ethyl
ester [112h] and 4-Methyl-5-trimethylsilanyl-pyrazole-1,3-dicarboxylic acid 1-
benzyl ester 3-ethyl ester [112i]
Isomer 1: Yellow oil; 'H NMR (CDCl 3, 400MHz) 6 7.48-7.35 (m, 5H), 5.44 (s, 2H), 4.24
(q, 2H, J= 7.1Hz), 2.20 (s, 3H), 1.26 (t, 3H, J = 7.1Hz) 0.37 (s, 9H). 13C NMR (CDCl 3,
100.6MHz) 6 161.98(s), 158.64(s), 155.50(s), 149.52 (s), 134.83(s), 134.71(s), 129.27,
129.02, 128.98, 70.29, 62.24, 14.35, 10.15, -0.96. LRMS (MH+) 361 Isomer 2: Yellow
oil; 1H NMR (CDCl 3, 400MHz) 6 7.52-7.33 (m, 5H), 5.50 (s, 2H), 4.42 (q, 2H, J =
7.1Hz), 2.39 (s, 3H), 1.41 (t, 3H, J = 7.1Hz) 0.36 (s, 9H). 13C NMR (CDCl 3, 100.6MHz)
6 163.01(s), 151.09(s), 146.65(s), 145.40(s), 134.85(s), 131.23(s), 129.35, 129.26, 129.02,
70.55, 61.66, 14.66, 11.10, 1.27. LRMS (MH+) 361.
4-Phenyl-5-trimethylsilanyl-4,5-dihydro-pyrazole-1,3-dicarboxylic acid 1-benzyl
ester 3-ethyl ester [113a] Yellow oil; 'H NMR (CDCl 3, 400MHz) 6 7.34-7.02 (m, 10H),
5.26 (d, 1H, J= 12.4Hz), 5.17 (d, 1H, J= 12.4Hz), 4.24 ( d, 1H, J=6.8Hz), 4.12-4.03 (m,
2H), 3.83 (d, 1H, J=6.8Hz), 1.10 (t, 3H, J= 7.2Hz), 0.00 (s, 9H); 13 C NMR (CDCl 3,
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100.6MHz) 6 163.00(s), 154.30 (s), 142.90 (s), 137.43(s), 130.77, 130.19, 130.05, 129.36,
128.81, 69.96, 63.40, 62.76, 54.75, 15.65, -1.25. HRMS (DCI / NH 3) calcd for
C23H 2 9N2 0 4Si (MH+) 425.1897; found 425.1884.
4
-Phenyl-4,5-dihydro-pyrazole-1,5-dicarboxylic acid 1-benzyl ester 5-ethyl ester
[113c]
Yellow oil; 'H NMR (CDCl 3, 400MHz) 6 7.28-7.17 (m, 8H), 7.04-7.01 (m, 2H), 6.79 (s,
1H), 5.21-5.07 (m, 2H), 4.53 ( d, 1H, J=5.2Hz), 4.22 (dd, 1H, J= 1.6, 5.6Hz), 4.15-4.01
(broad signal, 2H), 1.10 (broad signal, 3H); 13C NMR (CDCl3 100.6MHz) 6 167.69(s),
150.63 (s), 144.56, 135.23(s), 133.84(s), 127.57, 126.68, 126.61, 126.48, 125.48, 66.28,
64.12, 60.15, 55.86, 12.21. HRMS (El) caled for C2oH 2 ON2 O4 (M) 352.1423; found
352.1430.
4-Phenyl-pyrazole-1,5-dicarboxylic acid 1-benzyl ester 5-ethyl ester [113d]
Yellow oil; 11 NMR (CDCl3 400MHz) S 8.14 (s, 1H), 7.46-7.29 (m, 10H), 5.46 (s, 2H),
4.31 (q, 2H, J=7.lHz), 1.26 (t, 3H, J= 7.2Hz); 13C NMR (CDCl 3, 100.6MHz) 6 161.74(s),
148.78(s), 145.08(s), 141.03(s), 133.95(s), 130.67, 130.11(s), 129.18, 129.13, 128.83,
128.52, 128.22, 128.18, 70.72, 61.70, 14.10. LRMS (MH+) 351.
4-Phenyl-5-trimethylsilanyl-2H-pyrazole-3-carboxylic acid ethyl ester [113e]
Yellow oil; 'H NMR (CDCl3, 400MHz) 6 7.31-7.12 (m, 5H), 4.09 (q, 2H, J=7.1Hz), 1.05
(t, 3H, J= 7.0Hz), 0.00 (s, 9H); 13 C NMR (CDCl3 100.6MHz) 6 163.35, 144.66, 142.02,
134.67, 131.47, 129.70, 128.72, 128.58, 61.81, 15.18, 0.00. LRMS (MH+) 289.
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4. Conclusion
The kainoids are a class of non-proteinogenic pyrrolidine dicarboxylates that
exhibit both excitatory and excitotoxic activities. These activities are a result of the
ability of the kainoids to act as glutamate receptor agonists by activating ionotropic
glutamate receptors. The parent of this group of compounds is a-kainic acid. Kainic acid
is isolated from the seaweed Diginea simplex and has been used in Asian countries as a
treatment for intestinal worms in children. In addition it is used extensively by
neuropharmacologists for the study of glutamate receptors. Several years ago, the world's
sole supplier of kainic acid discontinued this product. Since that time, other sources have
appeared, however, the price of kainic acid remains significantly higher than it once was.
Numerous syntheses of kainoids have been published 136 however none have proven to be
practical. This is largely due to its synthetic challenge arising from the typical kainoid
skeleton containing three contiguous stereocenters in a trans (C2-C3), cis (C3-C4)
arrangement around the pyrrolidine ring. A less costly but still potent alternative to kainic
acid needs to be identified and available. It was envisaged that aza analogs of kainoids
would be less costly but potentially potent alternatives to kainic acid as supported by
molecular modeling evidence and theoretically their much easier synthetic accessibility. I
attempted to synthesize these aza analogs of kainoids via 1, 3-dipolar cycloadditions of
diazoalkanes with trans diethyl glutaconate followed by reduction of the resulting
cycloadducts and functional group transformations.
The 1, 3-dipolar cycloadditions of diazoalkanes (except TMS diazomethane) with
trans diethyl glutaconate yield 1-pyrazolines which have the expected regioselectivity,
being such that the terminal nitrogen of the diazoalkane is connected with the a-carbon
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of the ester. The 1-pyrazolines either isomerized to the 2-pyrazolines which may be
precursors to aza analogs of kainoids or became oxidized to the pyrazoles. The
isomerization of the 1-pyrazolines to the 2-pyrazolines with the direction of double bond
isomerization dependent on the substituents results in the loss of one of the newly formed
stereocenters.
The reduction of C=N double bond of the 2-pyrazolines would furnish the
pyrazolidine compounds which can be converted to aza analogs of kainoids after
functional group transformations. Such reduction has been successfully achieved for the
2-pyrazoline 69f which contains no subtituents at C-5 position around the pyrazoline ring
to afford the pyrazolidine compound 102 (Figure 34). Upon deprotection, the
pyrazolidine compound 102 can be converted to one of the synthetic targets 60 (Figure
18).
However, the reduction of the C=N double bond has not been achieved for the 2-
pyrazolines (protected or unprotected) which have C=N double bond conjugated to either
an ester group or a phenyl group. It was shown that the C=N double bond of these 2-
pyrazolines is resistant to the common C=N double bond reducing agents possibly due to
its conjugation with the carbonyl group or phenyl group. When the conjugation of the
C=N double bond with the ester group in the 2-pyrazoline 64d was interrupted by
reduction of that ester group to the hydroxyl group (Figure 32), the C=N double bond of
the resulting 2-pyrazoline 80 was easily reduced to afford the pyrazolidine compounds
99-101 (Figure 34) which may be converted to aza analog of kainoids 60 (Figure 18)
after functional group transformation. However, in contrast to the successful reduction of
the C=N double bond of the 2-pyrazoline 97 (Figure 33) with the superhydride, the
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reduction of the C=N double bond of 2-pyrazoline 94 (Figure 32) with the superhydride
was not achieved. This observation suggests that, besides the conjugation of the C=N
double bond to the ester group or the phenyl group, some other factors, such as the nature
of the C4 substituent, may also play a role in the resistance of the C=N double bond of
the 2 -pyrazolines towards the common C=N double bond reducing agents.
Although the orginal strategy to access the synthetic targets has not been realized,
its simpleness is so attractive that further efforts to directly reduce the cycloaddtion
products (either 1-pyrazolines or 2-pyrazolines) to the pyrazolidine compounds are still
worthwhile. Meanwhile, the successful conversion of the 2-pyrazoline 64d to the
pyrazolidine compounds 99-101 via the selective reduction of the ester group conjugated
to the C=N double bond followed by the reduction of the resulting isolated C=N double
bond suggests that the synthetic targets 58 and 59 may be accessed in a similar way. The
suggested route illustrated in Figure 35 may be used as an alternative to the original
strategy to access these two synthetic targets.
TMS diazomethane, due to the commercial availability, has been frequently used
as a synthetic reagent in 1, 3-dipolar cycloadditions, particularly in the preparation of
novel amino acid analogs. A survey of the recent literature indicates that the
regioselectivity of the double bond isomerization of TMS substituted 1-pyrazolines is
variable and at first glance, unpredictable. In an effort to develop a mechanistic rational
for the isomerization which could account for the products obtained, a systematic survey
of dipolar cycloadditions between TMS diazomethane and c, n-unsaturated
dipolarophiles was undertaken. Based on what I have obtained, I speculate that product
distributions of dipolar cycloadditions between TMS diazomethane and a, n-unsaturated
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dipolarophiles may be affected by the cycloaddition conditions, the reaction workup
conditions, and/or the nature of the dipolarophiles. Probably the cycloaddition reaction
and/or the isomerization of the 1-pyrazoline are so sensitive to the reaction conditions
and/or the reaction workup conditions that subtle change of these conditions results in
different product distributions. The complete picture of the cycloaddition of
trimethylsilyldiazomethane is under investigation.
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